<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title>BMC Medical Genetics</journal-title><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-10-49</article-id><article-id pub-id-type="pmid">19493349</article-id><article-id pub-id-type="doi">10.1186/1471-2350-10-49</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>118 SNPs of folate-related genes and risks of spina bifida and conotruncal heart defects</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Shaw</surname><given-names>Gary M</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I5">5</xref><email>gmshaw@stanford.edu</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Lu</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>wlu@ibt.tamhsc.edu</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Zhu</surname><given-names>Huiping</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>hzhu@ibt.tamsch.edu</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Yang</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>WYang@marchofdimes.com</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Briggs</surname><given-names>Farren BS</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>fbriggs@genepi.berkeley.edu</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Carmichael</surname><given-names>Suzan L</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I5">5</xref><email>SCarmichael@marchofdimes.com</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Barcellos</surname><given-names>Lisa F</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>barcello@genepi.berkeley.edu</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Lammer</surname><given-names>Edward J</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>elammer@chori.org</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Finnell</surname><given-names>Richard H</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>rfinnell@ibt.tamhsc.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Pediatrics, Division of Neonatal &#x00026; Developmental Medicine, Stanford University School of Medicine, Stanford, CA, USA</aff><aff id="I2"><label>2</label>Institute of Biosciences and Technology, Texas A&#x00026;M Health Science Center, Houston, TX, USA</aff><aff id="I3"><label>3</label>California Research Division, March of Dimes, California Research Division, Oakland, CA, USA</aff><aff id="I4"><label>4</label>School of Public Health, University of California, Berkeley, School of Public Health, Berkeley, CA, USA</aff><aff id="I5"><label>5</label>Children's Hospital Oakland Research Institute, Oakland, CA, USA</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>3</day><month>6</month><year>2009</year></pub-date><volume>10</volume><fpage>49</fpage><lpage>49</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/10/49"/><history><date date-type="received"><day>22</day><month>10</month><year>2008</year></date><date date-type="accepted"><day>3</day><month>6</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Shaw et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Shaw et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Shaw M Gary gmshaw@stanford.edu </dc:author><dc:title> 118 SNPs of folate-related genes and risks of spina bifida and conotruncal heart defects </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>BMC Medical Genetics 10(1): 49-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2350(2009)10:1&#x0003c;49&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2350</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Folic acid taken in early pregnancy reduces risks for delivering offspring with several congenital anomalies. The mechanism by which folic acid reduces risk is unknown. Investigations into genetic variation that influences transport and metabolism of folate will help fill this data gap. We focused on 118 SNPs involved in folate transport and metabolism.</p></sec><sec sec-type="methods"><title>Methods</title><p>Using data from a California population-based registry, we investigated whether risks of spina bifida or conotruncal heart defects were influenced by 118 single nucleotide polymorphisms (SNPs) associated with the complex folate pathway. This case-control study included 259 infants with spina bifida and a random sample of 359 nonmalformed control infants born during 1983&#x02013;86 or 1994&#x02013;95. It also included 214 infants with conotruncal heart defects born during 1983&#x02013;86. Infant genotyping was performed blinded to case or control status using a designed SNPlex assay. We examined single SNP effects for each of the 118 SNPs, as well as haplotypes, for each of the two outcomes.</p></sec><sec><title>Results</title><p>Few odds ratios (ORs) revealed sizable departures from 1.0. With respect to spina bifida, we observed ORs with 95% confidence intervals that did not include 1.0 for the following SNPs (heterozygous or homozygous) relative to the reference genotype: <italic>BHMT </italic>(rs3733890) OR = 1.8 (1.1&#x02013;3.1), <italic>CBS </italic>(rs2851391) OR = 2.0 (1.2&#x02013;3.1); <italic>CBS </italic>(rs234713) OR = 2.9 (1.3&#x02013;6.7); <italic>MTHFD1 </italic>(rs2236224) OR = 1.7 (1.1&#x02013;2.7); <italic>MTHFD1 </italic>(hcv11462908) OR = 0.2 (0&#x02013;0.9); <italic>MTHFD2 </italic>(rs702465) OR = 0.6 (0.4&#x02013;0.9); <italic>MTHFD2 </italic>(rs7571842) OR = 0.6 (0.4&#x02013;0.9); <italic>MTHFR </italic>(rs1801133) OR = 2.0 (1.2&#x02013;3.1); <italic>MTRR </italic>(rs162036) OR = 3.0 (1.5&#x02013;5.9); <italic>MTRR </italic>(rs10380) OR = 3.4 (1.6&#x02013;7.1); <italic>MTRR </italic>(rs1801394) OR = 0.7 (0.5&#x02013;0.9); <italic>MTRR </italic>(rs9332) OR = 2.7 (1.3&#x02013;5.3); <italic>TYMS </italic>(rs2847149) OR = 2.2 (1.4&#x02013;3.5); <italic>TYMS </italic>(rs1001761) OR = 2.4 (1.5&#x02013;3.8); and <italic>TYMS </italic>(rs502396) OR = 2.1 (1.3&#x02013;3.3). However, multiple SNPs observed for a given gene showed evidence of linkage disequilibrium indicating that the observed SNPs were not individually contributing to risk. We did not observe any ORs with confidence intervals that did not include 1.0 for any of the studied SNPs with conotruncal heart defects. Haplotype reconstruction showed statistical evidence of nonrandom associations with <italic>TYMS</italic>, <italic>MTHFR</italic>, <italic>BHMT </italic>and <italic>MTR </italic>for spina bifida.</p></sec><sec><title>Conclusion</title><p>Our observations do not implicate a particular folate transport or metabolism gene to be strongly associated with risks for spina bifida or conotruncal defects.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Periconceptional vitamin supplementation with folic acid substantially reduces risks of women having neural tube defect-affected pregnancies [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>] and has been implicated in reducing risks of several other congenital anomalies, including orofacial clefts and selected heart defects [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. Mechanisms underlying these reduced risks have not been elucidated, although it has been speculated that supplementation with vitamins containing folic acid restores some normal developmental function that is genetically compromised in selected infants.</p><p>Investigating genetic variation that influences cellular absorption, transport, and metabolism of folate may offer insight into this unknown developmentally protective mechanism. Indeed, numerous investigations of genes that are specifically involved with folate metabolism have yielded at least one gene, 5, 10-methylenetetrahydrofolate reductase (<italic>MTHFR</italic>), that has been associated with a modest increased risk of neural tube defects (e.g., [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B17">17</xref>]), and possibly heart defects [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. Observed risks with the two principal <italic>MTHFR </italic>variants, however, do not appear to account for a large proportion of the etiologic fraction of any of these defects, under the assumption that <italic>MTHFR </italic>variants have a causal role [<xref ref-type="bibr" rid="B17">17</xref>]. Thus, further investigation of other folate-related genes is necessary to reveal clues about mechanisms underlying the potential embryonic protective effects of folic acid supplementation.</p><p>We hypothesized that genetic susceptibility of fetal metabolism or transport of folate puts fetuses at risk for selected congenital anomalies. Using population-based data, we investigated 118 single nucleotide polymorphisms (SNPs) in 14 genes in the complex folate pathway as risk factors for spina bifida and conotruncal heart defects.</p></sec><sec sec-type="methods"><title>Methods</title><p>This population-based case-control study included infants with spina bifida or conotruncal heart defects diagnosed within 1 year after birth among infants and fetal deaths delivered to women residing in most California counties. Data were derived from the California Birth Defects Monitoring Program [<xref ref-type="bibr" rid="B20">20</xref>], a population-based active surveillance system for collecting information on infants and fetuses with congenital malformations. Diagnostic and demographic information was collected by program staff from multiple sources of medical records for all liveborn and stillborn fetuses (defined as &#x0003e;20 weeks gestation). Overall ascertainment for major malformations has been estimated as 97% complete [<xref ref-type="bibr" rid="B21">21</xref>]. Eligible were live born infants only because the source of DNA was from newborn screening cards.</p><p>Included were 259 infants with spina bifida and a random sample of 359 nonmalformed control infants born during 1983&#x02013;86 and 1994&#x02013;95 in selected counties in California. Also included for study were 214 infants with conotruncal heart defects, specifically d-transposition of the great arteries and tetralogy of Fallot. The random sample of 1983&#x02013;86 controls for conotruncal heart defects included 220 of the overall 359. Newborn bloodspots were obtained from the State of California and their use in this study was consistent with the consent procedures at the time of sample collection. The protocol for this study was reviewed and approved by the State of California Health and Welfare Agency Committee for the Protection of Human Subjects.</p><p>Genomic DNA was extracted from dried blood spots on filter paper using the Puregene DNA Extraction Kit (Gentra, Minneapolis, MN). Prior to genotyping, genomic DNA was amplified using a commercial multiple displacement amplification (MDA) kit, GenomePhi (GE Healthcare, Piscataway, NJ). The MDA method relies on isothermal amplification using the DNA polymerase of the bacteriophage phi29 and is a recently developed technique for high performance WGA. MDA has been demonstrated to be reliable for genotyping, with the most favorable call rates, best genomic coverage, and lowest amplification bias [<xref ref-type="bibr" rid="B22">22</xref>]. Studies indicate no discernable difference between WGA samples with GenomiPhi kit and the original DNA templates [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. The whole genome amplification (WGA) product was then quantified using RNase P method (AppliedBiosystems, Foster City, CA). 150 ng WGA product was then used for each SNPlex assay pool which contained about 48 SNPs.</p><p>Genotype analyses were performed using SNPlex assays (AppliedBiosystems, Foster City, CA). SNP markers were selected using the SNPBrowser&#x02122; program (version 3.0) provided by AppliedBiosystems Inc. This program allowed selection of SNP markers from the HapMap database. For each target gene, tagging SNPs were selected based on the pairwise r<sup>2 </sup>&#x0003e; = 0.8. SNPs with minor allele frequencies lower than 10% in Caucasians were excluded. All validated non-synonymous SNPs were included. Successful rates for SNPlex assays were &#x0003e;96% for 75 SNPs, from 90% to 96% for 32 SNPs, from 70% to 90% for 7 SNPs. 15 SNPs suffered from more than 30% failure rates. In a subsequent effort to fill in the missing genotyping data and obtain higher call rate, we performed TaqMan SNP assays (Appliedbiosystems, Foster City, CA) for 22 of these SNPs on an ABI 7900 Genetic Analyzer.</p><p>All genotyping was performed blinded to subject's case or control status. Case and control infants were genotyped for 129 SNPs. Failure to obtain unambiguous genotype data on &#x0003e;50% of the samples for 11 SNPs (<italic>CBS </italic>rs1801181 and rs12329790; <italic>MTHFR </italic>rs1537514 and rs7533315; <italic>MTR </italic>rs10925257, <italic>NOS3 </italic>rs1800780 and hcv11631000; <italic>RFC1 </italic>rs1051266, rs4819130, hcv16186310, and rs7278825) resulted in their elimination from further analyses. The remaining 118 SNPs are shown in Table <xref ref-type="table" rid="T1">1</xref>. The percentage of control study subjects (percentages were similar for cases) for whom genotype could be assigned is also shown in Table <xref ref-type="table" rid="T1">1</xref>.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Fourteen folate-related genes and 118 SNPs</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Gene</bold></td><td align="left"><bold>Change</bold></td><td align="right"><bold>Chromosome</bold></td><td align="right"><bold>Base Position</bold></td><td align="left"><bold>SNP_ID</bold></td><td align="left"><bold>Type/Comment</bold></td><td align="center"><bold>Percent Genotyped<sup>1</sup></bold></td></tr></thead><tbody><tr><td align="left"><italic>BHMT</italic></td><td align="left">R (A/G)</td><td align="right">5</td><td align="right">78457715</td><td align="left">rs3733890</td><td align="left">exon, nonsynonymous R239Q</td><td align="center">100</td></tr><tr><td align="left"><italic>BHMT</italic></td><td align="left">Y (C/T)</td><td align="right">5</td><td align="right">78471967</td><td align="left">rs1915706</td><td align="left">Intergenic/Unknown</td><td align="center">96.4</td></tr><tr><td align="left"><italic>BHMT</italic></td><td align="left">(G/C)</td><td align="right">5</td><td align="right">78567093</td><td align="left">rs1316753</td><td align="left">Tag, BHMT</td><td align="center">100</td></tr><tr><td align="left"><italic>BHMT</italic></td><td align="left">M (C/A)</td><td align="right">5</td><td align="right">78465350</td><td align="left">rs617219</td><td align="left">intergenic</td><td align="center">96.4</td></tr><tr><td align="left"><italic>BHMT</italic></td><td align="left">M (A/C)</td><td align="right">5</td><td align="right">78438303</td><td align="left">rs645112</td><td align="left">Intergenic/Unknown</td><td align="center">96.9</td></tr><tr><td align="left"><italic>BHMT</italic></td><td align="left">W (A/T)</td><td align="right">5</td><td align="right">78462964</td><td align="left">rs585800</td><td align="left">untranslated region</td><td align="center">94.2</td></tr><tr><td align="left"><italic>BHMT</italic></td><td align="left">S (C/G)</td><td align="right">5</td><td align="right">78559288</td><td align="left">rs3829809</td><td align="left">Tag, BHMT</td><td align="center">100</td></tr><tr><td align="left"><italic>BHMT</italic></td><td align="left">Y (C/T)</td><td align="right">5</td><td align="right">78452172</td><td align="left">rs567754</td><td align="left">intron</td><td align="center">95.8</td></tr><tr><td align="left"><italic>BHMT2</italic></td><td align="left">M (A/C)</td><td align="right">5</td><td align="right">78400443</td><td align="left">rs642431</td><td align="left">intergenic-BHMT2;intron-DMGDH</td><td align="center">91.1</td></tr><tr><td align="left"><italic>BHMT2</italic></td><td align="left">R (A/G)</td><td align="right">5</td><td align="right">78405657</td><td align="left">rs626105</td><td align="left">intron</td><td align="center">96.1</td></tr><tr><td align="left"><italic>BHMT2</italic></td><td align="left">Y (C/T)</td><td align="right">5</td><td align="right">78409187</td><td align="left">rs682985</td><td align="left">exon, synonymous</td><td align="center">95.5</td></tr><tr><td align="left"><italic>BHMT2</italic></td><td align="left">M (A/C)</td><td align="right">5</td><td align="right">78387392</td><td align="left">rs2253262</td><td align="left">exon, synonymous</td><td align="center">96.4</td></tr><tr><td align="left"><italic>BHMT2</italic></td><td align="left">K(G/T)</td><td align="right">5</td><td align="right">78402082</td><td align="left">rs670220</td><td align="left">Validated</td><td align="center">96.7</td></tr><tr><td align="left"><italic>BHMT2</italic></td><td align="left">R (A/G)</td><td align="right">5</td><td align="right">78404048</td><td align="left">rs592052</td><td align="left">intron</td><td align="center">99.2</td></tr><tr><td align="left"><italic>BHMT2</italic></td><td align="left">R (A/G)</td><td align="right">5</td><td align="right">78419219</td><td align="left">rs597560</td><td align="left">intron</td><td align="center">98.3</td></tr><tr><td align="left"><italic>CBS</italic></td><td align="left">Y (T/C)</td><td align="right">21</td><td align="right">43360473</td><td align="left">rs2851391</td><td align="left">intron</td><td align="center">92.5</td></tr><tr><td align="left"><italic>CBS</italic></td><td align="left">R (A/G)</td><td align="right">21</td><td align="right">43359173</td><td align="left">rs2298759</td><td align="left">intron</td><td align="center">72.4</td></tr><tr><td align="left"><italic>CBS</italic></td><td align="left">Y (T/C)</td><td align="right">21</td><td align="right">43361102</td><td align="left">rs234714</td><td align="left">intron</td><td align="center">90</td></tr><tr><td align="left"><italic>CBS</italic></td><td align="left">S (C/G)</td><td align="right">21</td><td align="right">43346936</td><td align="left">rs1051319</td><td align="left">untranslated region</td><td align="center">91.9</td></tr><tr><td align="left"><italic>CBS</italic></td><td align="left">Y (T/C)</td><td align="right">21</td><td align="right">43376503</td><td align="left">rs234784</td><td align="left">Tag, CBS</td><td align="center">99.7</td></tr><tr><td align="left"><italic>CBS</italic></td><td align="left">N (A/C/G/T)</td><td align="right">21</td><td align="right">43346760</td><td align="left">rs12613</td><td align="left">untranslated region</td><td align="center">92.5</td></tr><tr><td align="left"><italic>CBS</italic></td><td align="left">S (C/G)</td><td align="right">21</td><td align="right">43377074</td><td align="left">rs234785</td><td align="left">Tag, CBS</td><td align="center">100</td></tr><tr><td align="left"><italic>CBS</italic></td><td align="left">R (A/G)</td><td align="right">21</td><td align="right">43360960</td><td align="left">rs234713</td><td align="left">intron</td><td align="center">91.1</td></tr><tr><td align="left"><italic>CBS</italic></td><td align="left">Y (C/T)</td><td align="right">21</td><td align="right">43376312</td><td align="left">rs234783</td><td align="left">Tag, CBS</td><td align="center">100</td></tr><tr><td align="left"><italic>DHFR</italic></td><td align="left">Y(C/T)</td><td align="right">5</td><td align="right">79986537</td><td align="left">rs1650697</td><td align="left">Validated nsSNP</td><td align="center">92.2</td></tr><tr><td align="left"><italic>DHFR</italic></td><td align="left">W(A/T)</td><td align="right">5</td><td align="right">79957572</td><td align="left">rs12109877</td><td align="left">Validated</td><td align="center">94.2</td></tr><tr><td align="left"><italic>DHFR</italic></td><td align="left">Y(C/T)</td><td align="right">5</td><td align="right">79987790</td><td align="left">rs380691</td><td align="left">Validated</td><td align="center">95.5</td></tr><tr><td align="left"><italic>DHFR</italic></td><td align="left">M(A/C)</td><td align="right">5</td><td align="right">79985331</td><td align="left">rs1478834</td><td align="left">Validated</td><td align="center">96.4</td></tr><tr><td align="left"><italic>DHFR</italic></td><td align="left">Y(C/T)</td><td align="right">5</td><td align="right">79966012</td><td align="left">rs1643638</td><td align="left">Validated</td><td align="center">92.8</td></tr><tr><td align="left"><italic>DHFR</italic></td><td align="left">M(A/C)</td><td align="right">5</td><td align="right">79961366</td><td align="left">rs2618372</td><td align="left">Validated</td><td align="center">96.9</td></tr><tr><td align="left"><italic>DHFR</italic></td><td align="left">R (A/G)</td><td align="right">5</td><td align="right">79980489</td><td align="left">rs13161245</td><td align="left">Validated</td><td align="center">96.1</td></tr><tr><td align="left"><italic>DHFR</italic></td><td align="left">Y(C/T)</td><td align="right">5</td><td align="right">79975899</td><td align="left">rs1643650</td><td align="left">Validated</td><td align="center">94.7</td></tr><tr><td align="left"><italic>DHFR</italic></td><td align="left">K(G/T)</td><td align="right">5</td><td align="right">79981467</td><td align="left">rs836821</td><td align="left">Validated</td><td align="center">97.5</td></tr><tr><td align="left"><italic>FOLR1</italic></td><td align="left">Y (C/T)</td><td align="right">11</td><td align="right">73373406</td><td align="left">rs1540087</td><td align="left">untranslated region</td><td align="center">95.8</td></tr><tr><td align="left"><italic>FOLR1</italic></td><td align="left">W (T/A)</td><td align="right">11</td><td align="right">73380857</td><td align="left">rs11235462</td><td align="left">Tag, FOLR1</td><td align="center">100</td></tr><tr><td align="left"><italic>FOLR1</italic></td><td align="left">R (A/G)</td><td align="right">11</td><td align="right">73372879</td><td align="left">rs2071010</td><td align="left">untranslated region</td><td align="center">91.9</td></tr><tr><td align="left"><italic>FOLR2</italic></td><td align="left">R (A/G)</td><td align="right">11</td><td align="right">73404256</td><td align="left">rs2298444</td><td align="left">intron</td><td align="center">92.2</td></tr><tr><td align="left"><italic>FOLR2</italic></td><td align="left">R (A/G)</td><td align="right">11</td><td align="right">73402049</td><td align="left">rs514933</td><td align="left">intron</td><td align="center">100</td></tr><tr><td align="left"><italic>FOLR2</italic></td><td align="left">W (A/T)</td><td align="right">11</td><td align="right">73401368</td><td align="left">rs651646</td><td align="left">untranslated region</td><td align="center">100</td></tr><tr><td align="left"><italic>MTHFD1</italic></td><td align="left">Y (C/T)</td><td align="right">14</td><td align="right">63984935</td><td align="left">rs2236222</td><td align="left">intron</td><td align="center">95.5</td></tr><tr><td align="left"><italic>MTHFD1</italic></td><td align="left">Y (C/T)</td><td align="right">14</td><td align="right">63978904</td><td align="left">rs2236224</td><td align="left">intron</td><td align="center">97.8</td></tr><tr><td align="left"><italic>MTHFD1</italic></td><td align="left">Y (C/T)</td><td align="right">14</td><td align="right">63952133</td><td align="left">rs1950902</td><td align="left">exon, nonsynonymous</td><td align="center">90.5</td></tr><tr><td align="left"><italic>MTHFD1</italic></td><td align="left">Y (C/T)</td><td align="right">14</td><td align="right">63978598</td><td align="left">rs2236225</td><td align="left">exon, nonsynonymous G1958A (R653Q)</td><td align="center">100</td></tr><tr><td align="left"><italic>MTHFD1</italic></td><td align="left">(T/A)</td><td align="right">14</td><td align="right">63999040</td><td align="left">hCV11462908</td><td align="left">Tag, MTHFD1</td><td align="center">100</td></tr><tr><td align="left"><italic>MTHFD1</italic></td><td align="left">R (A/G)</td><td align="right">14</td><td align="right">63957808</td><td align="left">hCV11660794</td><td align="left">intron</td><td align="center">95.3</td></tr><tr><td align="left"><italic>MTHFD1</italic></td><td align="left">R (A/G)</td><td align="right">14</td><td align="right">63988165</td><td align="left">rs11849530</td><td align="left">intron</td><td align="center">95.8</td></tr><tr><td align="left"><italic>MTHFD1</italic></td><td align="left">R (A/G)</td><td align="right">14</td><td align="right">63990418</td><td align="left">rs1256146</td><td align="left">intron</td><td align="center">95</td></tr><tr><td align="left"><italic>MTHFD1</italic></td><td align="left">Y (C/T)</td><td align="right">14</td><td align="right">63985918</td><td align="left">rs10137921</td><td align="left">exon, nonsynonymous</td><td align="center">96.4</td></tr><tr><td align="left"><italic>MTHFD1</italic></td><td align="left">Y (C/T)</td><td align="right">14</td><td align="right">63980547</td><td align="left">rs1256142</td><td align="left">intron</td><td align="center">97.8</td></tr><tr><td align="left"><italic>MTHFD2</italic></td><td align="left">Y (T/C)</td><td align="right">2</td><td align="right">74304595</td><td align="left">rs11126426</td><td align="left">Intergenic, Tag</td><td align="center">100</td></tr><tr><td align="left"><italic>MTHFD2</italic></td><td align="left">(T/A)</td><td align="right">2</td><td align="right">74280806</td><td align="left">rs702465</td><td align="left">Intergenic, Tag</td><td align="center">96.7</td></tr><tr><td align="left"><italic>MTHFD2</italic></td><td align="left">R (A/G)</td><td align="right">2</td><td align="right">74313429</td><td align="left">rs1667599</td><td align="left">Intergenic, Tag</td><td align="center">100</td></tr><tr><td align="left"><italic>MTHFD2</italic></td><td align="left">R (A/G)</td><td align="right">2</td><td align="right">74340847</td><td align="left">rs1667627</td><td align="left">Validated</td><td align="center">96.1</td></tr><tr><td align="left"><italic>MTHFD2</italic></td><td align="left">W (A/T)</td><td align="right">2</td><td align="right">74333849</td><td align="left">rs828858</td><td align="left">Intergenic, Tag</td><td align="center">100</td></tr><tr><td align="left"><italic>MTHFD2</italic></td><td align="left">(C/G)</td><td align="right">2</td><td align="right">74281605</td><td align="left">rs702466</td><td align="left">Intergenic, Tag</td><td align="center">99.7</td></tr><tr><td align="left"><italic>MTHFD2</italic></td><td align="left">R (A/G)</td><td align="right">2</td><td align="right">74372559</td><td align="left">rs7571842</td><td align="left">Intergenic, Tag</td><td align="center">100</td></tr><tr><td align="left"><italic>MTHFD2</italic></td><td align="left">R (A/G)</td><td align="right">2</td><td align="right">74348376</td><td align="left">rs828903</td><td align="left">Validated</td><td align="center">94.4</td></tr><tr><td align="left"><italic>MTHFR</italic></td><td align="left">R (A/G)</td><td align="right">1</td><td align="right">11801310</td><td align="left">rs3737964</td><td align="left">Validated</td><td align="center">95.8</td></tr><tr><td align="left"><italic>MTHFR</italic></td><td align="left">R (A/G)</td><td align="right">1</td><td align="right">11823734</td><td align="left">rs535107</td><td align="left">Intergenic, Tag</td><td align="center">93.3</td></tr><tr><td align="left"><italic>MTHFR</italic></td><td align="left">K(G/T)</td><td align="right">1</td><td align="right">11798240</td><td align="left">rs1931226</td><td align="left">Validated</td><td align="center">96.9</td></tr><tr><td align="left"><italic>MTHFR</italic></td><td align="left">R(A/G)</td><td align="right">1</td><td align="right">11780518</td><td align="left">rs4846048</td><td align="left">Validated</td><td align="center">89.7</td></tr><tr><td align="left"><italic>MTHFR</italic></td><td align="left">Y (C/T)</td><td align="right">1</td><td align="right">11796598</td><td align="left">rs7525338</td><td align="left">Validated</td><td align="center">97.5</td></tr><tr><td align="left"><italic>MTHFR</italic></td><td align="left">R (A/G)</td><td align="right">1</td><td align="right">11785193</td><td align="left">rs2274976</td><td align="left">exon, nonsynonymous</td><td align="center">93</td></tr><tr><td align="left"><italic>MTHFR</italic></td><td align="left">Y (C/T)</td><td align="right">1</td><td align="right">11792217</td><td align="left">rs4846052</td><td align="left">intron</td><td align="center">96.9</td></tr><tr><td align="left"><italic>MTHFR</italic></td><td align="left">Y (C/T)</td><td align="right">1</td><td align="right">11790644</td><td align="left">rs1801133</td><td align="left">exon, nonsynonymous C677T</td><td align="center">99.4</td></tr><tr><td align="left"><italic>MTHFR</italic></td><td align="left">R (A/G)</td><td align="right">1</td><td align="right">11775209</td><td align="left">rs1889292</td><td align="left">Intergenic, Tag</td><td align="center">100</td></tr><tr><td align="left"><italic>MTHFR</italic></td><td align="left">Y (C/T)</td><td align="right">1</td><td align="right">11797323</td><td align="left">rs2066470</td><td align="left">exon, synonymous</td><td align="center">95.3</td></tr><tr><td align="left"><italic>MTHFR</italic></td><td align="left">R (A/G)</td><td align="right">1</td><td align="right">11788723</td><td align="left">rs4846051</td><td align="left">exon, synonymous</td><td align="center">93</td></tr><tr><td align="left"><italic>MTHFR</italic></td><td align="left">R (A/G)</td><td align="right">1</td><td align="right">11786566</td><td align="left">rs1476413</td><td align="left">intron</td><td align="center">93.9</td></tr><tr><td align="left"><italic>MTHFR</italic></td><td align="left">M (A/C)</td><td align="right">1</td><td align="right">11788742</td><td align="left">rs1801131</td><td align="left">exon, nonsynonymous A1298C</td><td align="center">99.7</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">M (A/C)</td><td align="right">1</td><td align="right">233374717</td><td align="left">rs2275565</td><td align="left">Validated</td><td align="center">96.1</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">Y (C/T)</td><td align="right">1</td><td align="right">233322616</td><td align="left">rs1806505</td><td align="left">intron</td><td align="center">97.5</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">K(G/T)</td><td align="right">1</td><td align="right">233386474</td><td align="left">rs3820571</td><td align="left">Validated</td><td align="center">96.1</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">Y (C/T)</td><td align="right">1</td><td align="right">233335898</td><td align="left">rs3754255</td><td align="left">Validated</td><td align="center">94.7</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">S(C/G)</td><td align="right">1</td><td align="right">233381346</td><td align="left">rs10802569</td><td align="left">Validated</td><td align="center">96.1</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">R (A/G)</td><td align="right">1</td><td align="right">233376992</td><td align="left">rs1266164</td><td align="left">intron</td><td align="center">96.1</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">R (A/G)</td><td align="right">1</td><td align="right">233374541</td><td align="left">rs1805087</td><td align="left">exon, nonsynonymous A2756G</td><td align="center">96.4</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">W(A/T)</td><td align="right">1</td><td align="right">233385428</td><td align="left">rs4659743</td><td align="left">Validated</td><td align="center">98.3</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">K(G/T)</td><td align="right">1</td><td align="right">233390667</td><td align="left">rs6676866</td><td align="left">Validated</td><td align="center">98.3</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">S(C/G)</td><td align="right">1</td><td align="right">233315110</td><td align="left">rs12060570</td><td align="left">Validated</td><td align="center">98.6</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">W(A/T)</td><td align="right">1</td><td align="right">233306545</td><td align="left">rs955516</td><td align="left">Validated</td><td align="center">99.2</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">K (G/T)</td><td align="right">1</td><td align="right">233313831</td><td align="left">rs4077829</td><td align="left">intron</td><td align="center">96.7</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">R (A/G)</td><td align="right">1</td><td align="right">233364202</td><td align="left">rs1770449</td><td align="left">intron</td><td align="center">94.4</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">S (C/G)</td><td align="right">1</td><td align="right">233353709</td><td align="left">rs3768139</td><td align="left">intron</td><td align="center">95.5</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">R (A/G)</td><td align="right">1</td><td align="right">233300165</td><td align="left">rs4659724</td><td align="left">intron</td><td align="center">97.2</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">Y (C/T)</td><td align="right">1</td><td align="right">233327367</td><td align="left">rs6668344</td><td align="left">intron</td><td align="center">96.4</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">R (A/G)</td><td align="right">1</td><td align="right">233367345</td><td align="left">rs7367859</td><td align="left">Validated</td><td align="center">93.9</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">K (G/T)</td><td align="right">1</td><td align="right">233354605</td><td align="left">rs3768142</td><td align="left">Validated</td><td align="center">96.1</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">Y (C/T)</td><td align="right">1</td><td align="right">233348403</td><td align="left">rs10925252</td><td align="left">Validated</td><td align="center">96.9</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">R (A/G)</td><td align="right">1</td><td align="right">233380610</td><td align="left">rs2229276</td><td align="left">exon, synonymous</td><td align="center">95</td></tr><tr><td align="left"><italic>MTR</italic></td><td align="left">R (A/G)</td><td align="right">1</td><td align="right">233388346</td><td align="left">rs1050993</td><td align="left">untranslated region</td><td align="center">97.2</td></tr><tr><td align="left"><italic>MTRR</italic></td><td align="left">R (A/G)</td><td align="right">5</td><td align="right">7938959</td><td align="left">rs162036</td><td align="left">Validated nsSNP Lys/Arg</td><td align="center">95.5</td></tr><tr><td align="left"><italic>MTRR</italic></td><td align="left">S (C/G)</td><td align="right">5</td><td align="right">7944506</td><td align="left">rs16879334</td><td align="left">exon, nonsynonymous Pro/Arg</td><td align="center">90</td></tr><tr><td align="left"><italic>MTRR</italic></td><td align="left">R (G/A)</td><td align="right">5</td><td align="right">7950319</td><td align="left">rs1802059</td><td align="left">exon, synonymous</td><td align="center">94.7</td></tr><tr><td align="left"><italic>MTRR</italic></td><td align="left">R (G/A)</td><td align="right">5</td><td align="right">7942216</td><td align="left">rs2287779</td><td align="left">exon, synonymous</td><td align="center">97.2</td></tr><tr><td align="left"><italic>MTRR</italic></td><td align="left">R (A/G)</td><td align="right">5</td><td align="right">7927847</td><td align="left">rs326120</td><td align="left">intron</td><td align="center">87.7</td></tr><tr><td align="left"><italic>MTRR</italic></td><td align="left">Y (C/T)</td><td align="right">5</td><td align="right">7950191</td><td align="left">rs10380</td><td align="left">exon, nonsynonymous, His/Tyr</td><td align="center">96.4</td></tr><tr><td align="left"><italic>MTRR</italic></td><td align="left">R (A/G)</td><td align="right">5</td><td align="right">7923973</td><td align="left">rs1801394</td><td align="left">exon, nonsynonymous</td><td align="center">96.7</td></tr><tr><td align="left"><italic>MTRR</italic></td><td align="left">Y (C/T)</td><td align="right">5</td><td align="right">7953712</td><td align="left">rs9332</td><td align="left">UTR</td><td align="center">92.2</td></tr><tr><td align="left"><italic>MTRR</italic></td><td align="left">S (C/G)</td><td align="right">5</td><td align="right">7938907</td><td align="left">rs10064631</td><td align="left">exon, nonsynonymous</td><td align="center">95</td></tr><tr><td align="left"><italic>MTRR</italic></td><td align="left">W (A/T)</td><td align="right">5</td><td align="right">7931424</td><td align="left">rs2303080</td><td align="left">exon, nonsynonymous</td><td align="center">96.1</td></tr><tr><td align="left"><italic>MTRR</italic></td><td align="left">R (A/G)</td><td align="right">5</td><td align="right">7949511</td><td align="left">rs3776455</td><td align="left">intron</td><td align="center">95</td></tr><tr><td align="left"><italic>MTRR</italic></td><td align="left">R (A/G)</td><td align="right">5</td><td align="right">7931179</td><td align="left">rs1532268</td><td align="left">exon, nonsynonymous</td><td align="center">95</td></tr><tr><td align="left"><italic>MTRR</italic></td><td align="left">R (A/G)</td><td align="right">5</td><td align="right">7945310</td><td align="left">rs162048</td><td align="left">intron</td><td align="center">98.6</td></tr><tr><td align="left"><italic>NOS3</italic></td><td align="left">R (A/G)</td><td align="right">7</td><td align="right">150145737</td><td align="left">rs891512</td><td align="left">intron</td><td align="center">86.6</td></tr><tr><td align="left"><italic>NOS3</italic></td><td align="left">R (A/G)</td><td align="right">7</td><td align="right">150127591</td><td align="left">rs1800779</td><td align="left">untranslated region</td><td align="center">87.5</td></tr><tr><td align="left"><italic>NOS3</italic></td><td align="left">Y (C/T)</td><td align="right">7</td><td align="right">150148555</td><td align="left">rs3918211</td><td align="left">exon, synonymous</td><td align="center">96.9</td></tr><tr><td align="left"><italic>RFC1</italic></td><td align="left">K (G/T)</td><td align="right">21</td><td align="right">45761011</td><td align="left">rs3788189</td><td align="left">intron</td><td align="center">81.1</td></tr><tr><td align="left"><italic>RFC1</italic></td><td align="left">R (A/G)</td><td align="right">21</td><td align="right">45755537</td><td align="left">rs12483377</td><td align="left">Tag, RFC</td><td align="center">100</td></tr><tr><td align="left"><italic>RFC1</italic></td><td align="left">R (A/G)</td><td align="right">21</td><td align="right">45756112</td><td align="left">rs2236484</td><td align="left">Intron, Tag</td><td align="center">98.6</td></tr><tr><td align="left"><italic>RFC1</italic></td><td align="left">R (A/G)</td><td align="right">21</td><td align="right">45761386</td><td align="left">rs3788190</td><td align="left">Intron, Tag</td><td align="center">91.1</td></tr><tr><td align="left"><italic>RFC1</italic></td><td align="left">S (C/G)</td><td align="right">21</td><td align="right">45750430</td><td align="left">rs10483080</td><td align="left">intron</td><td align="center">99.7</td></tr><tr><td align="left"><italic>RFC1</italic></td><td align="left">Y (C/T)</td><td align="right">21</td><td align="right">45777720</td><td align="left">rs2330183</td><td align="left">intron</td><td align="center">91.4</td></tr><tr><td align="left"><italic>TYMS</italic></td><td align="left">Y (C/T)</td><td align="right">18</td><td align="right">652215</td><td align="left">rs11540152</td><td align="left">exon, nonsynonymous</td><td align="center">95.8</td></tr><tr><td align="left"><italic>TYMS</italic></td><td align="left">Y (C/T)</td><td align="right">18</td><td align="right">660414</td><td align="left">rs2853532</td><td align="left">intron</td><td align="center">96.4</td></tr><tr><td align="left"><italic>TYMS</italic></td><td align="left">R (A/G)</td><td align="right">18</td><td align="right">656371</td><td align="left">rs2847149</td><td align="left">intron</td><td align="center">97.2</td></tr><tr><td align="left"><italic>TYMS</italic></td><td align="left">Y (C/T)</td><td align="right">18</td><td align="right">652103</td><td align="left">rs1001761</td><td align="left">intron</td><td align="center">98.9</td></tr><tr><td align="left"><italic>TYMS</italic></td><td align="left">Y (C/T)</td><td align="right">18</td><td align="right">649236</td><td align="left">rs502396</td><td align="left">intron</td><td align="center">97.8</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>Percent of 359 controls genotyped for each SNP.</p><p>Abbreviations: <italic>BHMT </italic>= betaine homocysteine methyltransferase; <italic>BHMT2 </italic>betaine homocysteine methyltransferase-2; <italic>CBS </italic>= cystathione beta synthase; <italic>DHFR </italic>= dihydrofolate reductase; <italic>FOLR1 </italic>folate receptor 1; <italic>FOLR2 </italic>folate receptor 2; <italic>MTHFD1 </italic>= methylenetetrahydrofolate dehydrogenase 1; <italic>MTHFD2 </italic>= methylenetetrahydrofolate dehydrogenase 2; <italic>MTHFR </italic>= methylenetetrahydrofolate reductase; <italic>MTR </italic>= methionine synthase; <italic>MTRR </italic>= methionine synthase reductase; <italic>NOS3 </italic>= nitric oxide synthase; <italic>RFC1 </italic>= reduced folate carrier 1; <italic>TYMS </italic>= thymidylate synthase.</p></table-wrap-foot></table-wrap><p>Genotypes among controls were analyzed to verify that their distributions fit Hardy-Weinberg expectations. Genotypes for each SNP were statistically consistent with Hardy-Weinberg expectations. Odds ratios and 95% confidence intervals (CI) were used to estimate risks. These measures were calculated using SAS software (version 9.1). Information on maternal race/ethnicity was obtained for case and control infants from California birth certificates. Logistic regression was used to compute risk estimates adjusted for maternal race/ethnicity (white Hispanic; white nonHispanic, and other). Analyses estimated defect risks (spina bifida or conotruncal heart defects) for each SNP assuming a recessive model, i.e., homozygous variant genotype compared to homozygous reference genotype and heterozygous variant genotype compared to homozygous reference genotype. In addition to single SNP-at-a-time analyses, we explored haplotype block analyses. Haplotype analyses were performed using Haploview version 3.32. Identified blocks were assessed with odds ratios.</p></sec><sec><title>Results</title><p>Numbers of case and control infants stratified by race/ethnicity are shown in Table <xref ref-type="table" rid="T2">2</xref>. These data show the expected greater frequency of Hispanics in the spina bifida case group.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Racial/ethnic percentages of malformed cases and non-malformed controls, California 1983&#x02013;86 and 1994&#x02013;95.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="2"><bold>Spina Bifida</bold></td><td align="center" colspan="2"><bold>Conotruncal Heart</bold></td></tr></thead><tbody><tr><td></td><td align="center">Cases<break/>n = 259<break/>%<sup>2</sup></td><td align="center">Controls<break/>n = 359<break/>%<sup>2</sup></td><td align="center">Cases<break/>n = 214<break/>%<sup>2</sup></td><td align="center">Controls<break/>n = 220<sup>1</sup><break/>%<sup>2</sup></td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>Race/Ethnicity</bold></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">White, Hispanic</td><td align="center">50.6</td><td align="center">31.5</td><td align="center">17.8</td><td align="center">18.6</td></tr><tr><td align="left">White, nonHispanic</td><td align="center">35.9</td><td align="center">47.4</td><td align="center">53.3</td><td align="center">61.8</td></tr><tr><td align="left">Other</td><td align="center">12.0</td><td align="center">20.6</td><td align="center">26.2</td><td align="center">18.6</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>The number of controls born in the period 1983&#x02013;86 among the 359 selected for the overall study period 1983&#x02013;86 and 1994&#x02013;95. The 220 represent the birth years of cases with conotruncal heart defects.</p><p><sup>2</sup>Percentages may not equal 100 owing to missing data or rounding.</p></table-wrap-foot></table-wrap><p>We examined risks for each of the 118 SNPs and for each of the two birth defect outcome (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). Few odds ratios (ORs) revealed sizable departures from 1.0. Given the large number of comparisons (n = 472) we expected more ORs to be substantially different from 1.0 by chance. With respect to spina bifida, we observed ORs with confidence intervals that did not include 1.0 for the following SNPs (heterozygous or homozygous) relative to the reference genotype: <italic>BHMT </italic>(rs3733890) OR = 1.8 (1.1&#x02013;3.1), <italic>CBS </italic>(rs2851391) OR = 2.0 (1.2&#x02013;3.1); <italic>CBS </italic>(rs234713) OR = 2.9 (1.3&#x02013;6.7); <italic>MTHFD1 </italic>(rs2236224) OR = 1.7 (1.1&#x02013;2.7); <italic>MTHFD1 </italic>(hcv11462908) OR = 0.2 (0&#x02013;0.9); <italic>MTHFD2 </italic>(rs702465) OR = 0.6 (0.4&#x02013;0.9); <italic>MTHFD2 </italic>(rs7571842) OR = 0.6 (0.4&#x02013;0.9); <italic>MTHFR </italic>(rs1801133) OR = 2.0 (1.2&#x02013;3.1); <italic>MTRR </italic>(rs162036) OR = 3.0 (1.5&#x02013;5.9); <italic>MTRR </italic>(rs10380) OR = 3.4 (1.6&#x02013;7.1); <italic>MTRR </italic>(rs1801394) OR = 0.7 (0.5&#x02013;0.9); <italic>MTRR </italic>(rs9332) OR = 2.7 (1.3&#x02013;5.3); <italic>TYMS </italic>(rs2847149) OR = 2.2 (1.4&#x02013;3.5); <italic>TYMS </italic>(rs1001761) OR = 2.4 (1.5&#x02013;3.8); and <italic>TYMS </italic>(rs502396) OR = 2.1 (1.3&#x02013;3.3). Each gene involving multiple SNP associations was investigated for linkage disequilibrium. Modest to strong evidence for linkage disequilibrium was observed for SNPs in each gene, i.e., D' ranged from 0.44 to 1.0 with all p values &#x0003c; 10<sup>-4</sup>. With respect to conotruncal heart defects, we did not observe any OR with a confidence interval that did not include 1.0.</p><p>We did not observe evidence to indicate that risk patterns were confounded by race/ethnicity groupings, i.e., observed ORs were not substantially altered after adjusting for maternal race/ethnicity (not shown, available from authors upon request).</p><p>Haplotypes, reconstructed for each gene based on studied SNPs, were explored to assess risks for each case group. A total of 77 of the 118 studied SNPs formed 17 haplotype blocks. As shown in Table <xref ref-type="table" rid="T3">3</xref>, blocks for <italic>TYMS</italic>, <italic>MTHFR</italic>, <italic>BHMT</italic>, and <italic>MTR </italic>showed some evidence of nonrandom effects for spina bifida. For each of these haplotypes we observed decreased risk associated with the lower frequency haplotype relative to the most frequent haplotype. Similar to SNP analyses, haplotype analyses for conotruncal heart defects did not reveal evidence of nonrandom effects, with the exception of one haplotype block for <italic>MTR </italic>(Table <xref ref-type="table" rid="T4">4</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Haplotype associations with risks of spina bifida</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Haplotype Block</bold></td><td align="right"><bold>Frequency</bold></td><td align="center"><bold>Odds Ratio (95% CI)</bold></td></tr></thead><tbody><tr><td align="left"><bold><italic>TYMS</italic></bold></td><td></td><td></td></tr><tr><td align="left">CGC</td><td align="right">0.500</td><td align="center">REF</td></tr><tr><td align="left">TAT</td><td align="right">0.373</td><td align="center">0.7 (0.6&#x02013;0.9)</td></tr><tr><td align="left">TAC</td><td align="right">0.115</td><td align="center">0.5 (0.3&#x02013;0.7)</td></tr><tr><td align="left"><bold><italic>MTRR</italic></bold></td><td></td><td></td></tr><tr><td align="left">ATTAGCAACAC</td><td align="right">0.264</td><td align="center">REF</td></tr><tr><td align="left">ACTGGCAGTGT</td><td align="right">0.213</td><td align="center">1.4 (1.0&#x02013;1.9)</td></tr><tr><td align="left">ACTAGCAACGC</td><td align="right">0.201</td><td align="center">0.8 (0.6&#x02013;1.1)</td></tr><tr><td align="left">GCTAGCGGCGC</td><td align="right">0.162</td><td align="center">1.1 (0.7&#x02013;1.5)</td></tr><tr><td align="left">ACAAAGAGCGC</td><td align="right">0.055</td><td align="center">1.1 (0.7&#x02013;1.9)</td></tr><tr><td align="left">ACTAGCAGCGC</td><td align="right">0.034</td><td align="center">0.6 (0.3&#x02013;1.3)</td></tr><tr><td align="left">ACTAAGAGCGC</td><td align="right">0.027</td><td align="center">1.2 (0.6&#x02013;2.6)</td></tr><tr><td align="left">ACTGGCAGCGT</td><td align="right">0.011</td><td align="center">1.4 (0.5&#x02013;4.1)</td></tr><tr><td align="left"><bold><italic>MTHFR</italic></bold>*</td><td></td><td></td></tr><tr><td align="left">GGG</td><td align="right">0.656</td><td align="center">REF</td></tr><tr><td align="left">AGA</td><td align="right">0.163</td><td align="center">0.9 (0.6&#x02013;1.2)</td></tr><tr><td align="left">AGG</td><td align="right">0.121</td><td align="center">0.9 (0.6&#x02013;1.2)</td></tr><tr><td align="left">AAA</td><td align="right">0.057</td><td align="center">0.6 (0.3&#x02013;1.0)</td></tr><tr><td align="left"><bold><italic>MTHFR</italic></bold>**</td><td></td><td></td></tr><tr><td align="left">TCCCA</td><td align="right">0.368</td><td align="center">REF</td></tr><tr><td align="left">CCCCA</td><td align="right">0.231</td><td align="center">0.7 (0.5&#x02013;0.9)</td></tr><tr><td align="left">CTCTG</td><td align="right">0.180</td><td align="center">0.8 (0.6&#x02013;1.1)</td></tr><tr><td align="left">CTTCG</td><td align="right">0.099</td><td align="center">0.6 (0.4&#x02013;0.9)</td></tr><tr><td align="left">CTCCG</td><td align="right">0.063</td><td align="center">0.7 (0.5&#x02013;1.2)</td></tr><tr><td align="left">CTCCA</td><td align="right">0.037</td><td align="center">1.0 (0.5&#x02013;1.8)</td></tr><tr><td align="left"><bold><italic>CBS</italic></bold></td><td></td><td></td></tr><tr><td align="left">CG</td><td align="right">0.889</td><td align="center">REF</td></tr><tr><td align="left">TC</td><td align="right">0.055</td><td align="center">1.2 (0.7&#x02013;1.9)</td></tr><tr><td align="left">CC</td><td align="right">0.053</td><td align="center">0.6 (0.3&#x02013;1.0)</td></tr><tr><td align="left"><bold><italic>RFC1</italic></bold>*</td><td></td><td></td></tr><tr><td align="left">CG</td><td align="right">0.856</td><td align="center">REF</td></tr><tr><td align="left">GG</td><td align="right">0.079</td><td align="center">1.1 (0.7&#x02013;1.7)</td></tr><tr><td align="left">GA</td><td align="right">0.063</td><td align="center">1.0 (0.6&#x02013;1.6)</td></tr><tr><td align="left"><bold><italic>RFC1</italic></bold>**</td><td></td><td></td></tr><tr><td align="left">TG</td><td align="right">0.486</td><td align="center">REF</td></tr><tr><td align="left">GA</td><td align="right">0.463</td><td align="center">0.9 (0.7&#x02013;1.2)</td></tr><tr><td align="left">GG</td><td align="right">0.046</td><td align="center">0.6 (0.3&#x02013;1.0)</td></tr><tr><td align="left"><bold><italic>MTHFD1</italic></bold>*</td><td></td><td></td></tr><tr><td align="left">CT</td><td align="right">0.486</td><td align="center">REF</td></tr><tr><td align="left">TC</td><td align="right">0.429</td><td align="center">1.3 (1.0&#x02013;1.6)</td></tr><tr><td align="left">CC</td><td align="right">0.080</td><td align="center">0.9 (0.6&#x02013;1.4)</td></tr><tr><td align="left"><bold><italic>MTHFD1</italic></bold>**</td><td></td><td></td></tr><tr><td align="left">GT</td><td align="right">0.825</td><td align="center">REF</td></tr><tr><td align="left">AA</td><td align="right">0.167</td><td align="center">0.9 (0.6&#x02013;1.2)</td></tr><tr><td align="left"><bold><italic>FOLR2</italic></bold></td><td></td><td></td></tr><tr><td align="left">TA</td><td align="right">0.549</td><td align="center">REF</td></tr><tr><td align="left">AG</td><td align="right">0.356</td><td align="center">1.0 (0.8&#x02013;1.3)</td></tr><tr><td align="left">AA</td><td align="right">0.093</td><td align="center">1.0 (0.7&#x02013;1.6)</td></tr><tr><td align="left"><bold><italic>MTHFD2</italic></bold>*</td><td></td><td></td></tr><tr><td align="left">TA</td><td align="right">0.589</td><td align="center">REF</td></tr><tr><td align="left">CA</td><td align="right">0.321</td><td align="center">1.1 (0.9&#x02013;1.4)</td></tr><tr><td align="left">CG</td><td align="right">0.089</td><td align="center">1.1 (0.7&#x02013;1.6)</td></tr><tr><td align="left"><bold><italic>MTHFD2</italic></bold>**</td><td></td><td></td></tr><tr><td align="left">TC</td><td align="right">0.388</td><td align="center">REF</td></tr><tr><td align="left">TT</td><td align="right">0.332</td><td align="center">1.2 (0.9&#x02013;1.5)</td></tr><tr><td align="left">AT</td><td align="right">0.276</td><td align="center">1.0 (0.8&#x02013;1.4)</td></tr><tr><td align="left"><bold><italic>BHMT2</italic></bold></td><td></td><td></td></tr><tr><td align="left">GGGTCA</td><td align="right">0.466</td><td align="center">REF</td></tr><tr><td align="left">TAACTC</td><td align="right">0.219</td><td align="center">1.0 (0.7&#x02013;1.3)</td></tr><tr><td align="left">GAGCTC</td><td align="right">0.171</td><td align="center">1.1 (0.8&#x02013;1.6)</td></tr><tr><td align="left">GAGTCA</td><td align="right">0.091</td><td align="center">1.0 (0.6&#x02013;1.5)</td></tr><tr><td align="left">GGGTCC</td><td align="right">0.022</td><td align="center">0.7 (0.3&#x02013;1.7)</td></tr><tr><td align="left"><bold><italic>BHMT</italic></bold>*</td><td></td><td></td></tr><tr><td align="left">CAA</td><td align="right">0.339</td><td align="center">REF</td></tr><tr><td align="left">TGA</td><td align="right">0.326</td><td align="center">0.7 (0.5&#x02013;0.9)</td></tr><tr><td align="left">CGT</td><td align="right">0.172</td><td align="center">0.7 (0.5&#x02013;1.0)</td></tr><tr><td align="left">CGA</td><td align="right">0.158</td><td align="center">0.9 (0.6&#x02013;1.2)</td></tr><tr><td align="left"><bold><italic>BHMT</italic></bold>**</td><td></td><td></td></tr><tr><td align="left">AC</td><td align="right">0.501</td><td align="center">REF</td></tr><tr><td align="left">CT</td><td align="right">0.373</td><td align="center">0.8 (0.7&#x02013;1.1)</td></tr><tr><td align="left">AT</td><td align="right">0.120</td><td align="center">0.9 (0.6&#x02013;1.3)</td></tr><tr><td align="left"><bold><italic>DHFR</italic></bold></td><td></td><td></td></tr><tr><td align="left">CTTACCA</td><td align="right">0.402</td><td align="center">REF</td></tr><tr><td align="left">CTTACCG</td><td align="right">0.390</td><td align="center">0.9 (0.7&#x02013;1.2)</td></tr><tr><td align="left">ACCGAAA</td><td align="right">0.201</td><td align="center">0.9 (0.7&#x02013;1.3)</td></tr><tr><td align="left"><bold><italic>MTR</italic></bold></td><td></td><td></td></tr><tr><td align="left">AATCTTTCCTAGAGGGCTTGG</td><td align="right">0.373</td><td align="center">REF</td></tr><tr><td align="left">GTGGCCCTGGGAAGAAGAGAT</td><td align="right">0.262</td><td align="center">1.0 (0.7&#x02013;1.3)</td></tr><tr><td align="left">GTGGCCCTCTAGGTGACTTGG</td><td align="right">0.190</td><td align="center">0.9 (0.7&#x02013;1.3)</td></tr><tr><td align="left">GTGGCCCTGGGGAGAAGAGAT</td><td align="right">0.045</td><td align="center">1.4 (0.8&#x02013;2.5)</td></tr><tr><td align="left">GTGGCCTTCTAGATGACTTGT</td><td align="right">0.040</td><td align="center">0.6 (0.3&#x02013;1.2)</td></tr><tr><td align="left">GTGGCCCTCGAAAGGAGTTGT</td><td align="right">0.032</td><td align="center">0.3 (0.1&#x02013;0.6)</td></tr></tbody></table><table-wrap-foot><p><bold><italic>TYMS </italic></bold>included rs1001761, rs2847149 and, rs2853532; <bold><italic>MTRR </italic></bold>included rs326120, rs1532268, rs2303080, rs162036, rs2287779, rs16879334, rs162048, rs3776455, rs10380</p><p>rs1802059, and rs9332; <bold><italic>MTHFR</italic></bold>* included rs1889292, rs2274976, and rs1476413; <bold><italic>MTHFR</italic></bold>** included rs1801133, rs4846052, rs2066470, rs3737964, and rs535107; <bold><italic>CBS </italic></bold>included rs12613 and rs 1051319; <bold><italic>RFC1</italic></bold>* included rs10483080 and rs12483377; <bold><italic>RFC1</italic></bold>** included rs3788189 and rs3788190; <bold><italic>MTHFD1</italic></bold>* included rs2236224 and rs1256142; <bold><italic>MTHFD1</italic></bold>** included rs1256146 and hcv11462908; <bold><italic>FOLR2 </italic></bold>included rs651646 and rs514933; <bold><italic>MTHFD2</italic></bold>* included rs11126426 and rs1667599; <bold><italic>MTHFD2</italic></bold>** included rs828858 and rs1667627; <bold><italic>BHMT2 </italic></bold>included rs670220, rs592052, rs626105, rs682985, rs597560, and rs645112; <bold><italic>BHMT</italic></bold>* included rs567754, rs3733890, and rs585800; <bold><italic>BHMT</italic></bold>** included rs617219 and rs1915706; <bold><italic>DHFR </italic></bold>included rs2618372, rs1643638, rs1643650, rs13161245, rs836821, rs1478834, and rs380691; <bold><italic>MTR </italic></bold>included rs4659724, rs955516, rs4077829, rs12060570, rs1806505, rs6668344, rs3754255, rs10925252, rs3768139, rs3768142, rs1770449, rs7367859, rs1805087, rs2275565, rs1266164, rs2229276, rs10802569, rs4659743, rs3820571, rs1050993, and rs6676866.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Haplotype association with risks of conotruncal heart defects</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Haplotype</bold></td><td align="right"><bold>Frequency</bold></td><td align="center"><bold>Odds Ratios (95% CI)</bold></td></tr></thead><tbody><tr><td align="left"><bold>Block 19 (<italic>MTR</italic>)</bold></td><td></td><td></td></tr><tr><td align="left">AATCTTTCCTAGAGGGCTTGG</td><td align="right">0.354</td><td align="center">REF</td></tr><tr><td align="left">GTGGCCCTGGGAAGAAGAGAT</td><td align="right">0.272</td><td align="center">1.1 (0.7&#x02013;1.5)</td></tr><tr><td align="left">GTGGCCCTCTAGGTGACTTGG</td><td align="right">0.189</td><td align="center">1.2 (0.8&#x02013;1.8)</td></tr><tr><td align="left">GTGGCCTTCTAGATGACTTGT</td><td align="right">0.048</td><td align="center">1.5 (0.8&#x02013;3.0)</td></tr><tr><td align="left">GTGGCCCTCGAAAGGAGTTGT</td><td align="right">0.035</td><td align="center">1.0 (0.5&#x02013;2.1)</td></tr><tr><td align="left">GTGGCCCTGGGGAGAAGAGAT</td><td align="right">0.021</td><td align="center">0.9 (0.3&#x02013;2.2)</td></tr><tr><td align="left">GATCTTTCCTAGAGGGCTTGG</td><td align="right">0.013</td><td align="center">10.7 (1.4&#x02013;84.8)</td></tr></tbody></table><table-wrap-foot><p>Block 19 included rs4659724, rs955516, rs4077829, rs12060570, rs1806505, rs6668344, rs3754255, rs10925252, rs3768139, rs3768142, rs1770449, rs7367859, rs1805087, rs2275565, rs1266164, rs2229276, rs10802569, rs4659743, rs3820571, rs1050993, and</p><p>rs6676866.</p></table-wrap-foot></table-wrap><p>Haplotype analyses were stratified by race/ethnic background (Hispanic white and nonHispanic white). We observed evidence of a nonrandom haplotype association with <italic>TYMS </italic>for spina bifida and conotruncal heart defects among nonHispanic whites. Lack of evidence for other haplotypes that were observed overall was likely the result of smaller sample sizes from stratification.</p></sec><sec><title>Discussion</title><p>In this California population we found only modest evidence that polymorphisms in 14 folate-related genes contributed to risk of spina bifida. SNPs contributing risks were in <italic>BHMT</italic>, <italic>CBS</italic>, <italic>MTHFD1</italic>, <italic>MTHFD2</italic>, <italic>MTHFR</italic>, <italic>MTRR</italic>, and <italic>TYMS</italic>. Haplotype association analyses further identified <italic>TYMS </italic>and <italic>MTHFR </italic>as potential contributors to spina bifida risk. In general, however, most of these folate-related genes showed little evidence for a gene-only effect on risk of spina bifida, and even less, on risks of conotruncal heart defects.</p><p>The 14 genes studied here have been implicated in the complex metabolic cycle involving folate (e.g., [<xref ref-type="bibr" rid="B25">25</xref>-<xref ref-type="bibr" rid="B27">27</xref>]). To our knowledge, this study contained the largest number of SNPs in folate-related genes interrogated as risk factors for human spina bifida or conotruncal heart defects. Previous studies have included some of the SNPs examined here. For example, Boyles and colleagues [<xref ref-type="bibr" rid="B28">28</xref>] studied 28 SNPs in 11 folate-related genes and found that only <italic>BHMT </italic>(rs3733890) was associated with increased spina bifida risk. This <italic>BHMT </italic>association is consistent with our findings that showed an odds ratio of 1.8 (1.1&#x02013;3.1).</p><p>Many studies have explored <italic>MTHFR </italic>677 (rs1801133) polymorphism. A range of risks, including no-effect, has been reported for this SNP relative to spina bifida. Botto and Yang [<xref ref-type="bibr" rid="B15">15</xref>] in a meta-analysis demonstrated a pooled odds ratio of 1.8 for spina bifida among infants homozygous for 677T. A few studies have also explored this 677 SNP in <italic>MTHFR </italic>as a risk factor for selected congenital heart defects, with most investigations finding no or little association [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B31">31</xref>]. We did observe a 2-fold increased risk of spina bifida associated with this SNP for homozygous infants. Further, haplotype analyses showed some association for the <italic>MTHFR </italic>gene as well.</p><p>Methionine synthase (MTR) is a vitamin B<sub>12 </sub>dependent enzyme that is essential for the remethylation of homocysteine to methionine. The enzyme is required by cells for the essential accumulation of folate [<xref ref-type="bibr" rid="B32">32</xref>]. One particular SNP (A2756G; rs1805087) has been considerably investigated, with increased risks of NTDs reported in some studies [<xref ref-type="bibr" rid="B33">33</xref>-<xref ref-type="bibr" rid="B35">35</xref>], but not in others [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B37">37</xref>]. We did not find an increased risk for spina bifida or conotruncal heart defects associated with this SNP or any other SNP of <italic>MTR</italic>.</p><p>Cystathione beta synthase (CBS) is critical to the degradation of homocysteine to cysteine. Regulation of this pyridoxal phosphate-dependent enzyme catalyzes the hydroxyl group of serine with the thiolate of homocysteine [<xref ref-type="bibr" rid="B38">38</xref>]. The polymorphism in the <italic>CBS </italic>gene that has received the most study is a 68 bp insertion (844ins68), with predominantly no associations observed for NTDs [<xref ref-type="bibr" rid="B27">27</xref>]. This polymorphism was not investigated in the current study. We did observe, however, two <italic>CBS </italic>SNPs (rs2851391 and rs234713) that showed increased risks for spina bifida. Boyles et al [<xref ref-type="bibr" rid="B28">28</xref>], albeit using a different study design than ours, observed that these two SNPs were not differentially transmitted from parents of infants with spina bifida.</p><p><italic>MTRR </italic>gene polymorphisms (particularly rs1801394) have been investigated as a risk factor for both spina bifida and congenital heart defects. Polymorphisms in <italic>MTRR </italic>could alter homocysteine levels because methionine synthase reductase participates in maintaining the vitamin B<sub>12</sub>-dependent conversion of homocysteine to methionine [<xref ref-type="bibr" rid="B32">32</xref>]. The most frequently studied <italic>MTRR </italic>polymorphism has been the 66A&#x0003e;G (rs1801394). This polymorphism in infants was associated with a 2.6-fold increased risk of spina bifida in an earlier study by us [<xref ref-type="bibr" rid="B33">33</xref>], it was associated with increased risk for spina bifida in another study only when vitamin B<sub>12 </sub>levels were low [<xref ref-type="bibr" rid="B39">39</xref>], or in combination with MTHFR CC genotype [<xref ref-type="bibr" rid="B35">35</xref>]. The polymorphism in mothers of infants with neural tube defects has been associated with increased risk in one study [<xref ref-type="bibr" rid="B40">40</xref>], but not in another study [<xref ref-type="bibr" rid="B41">41</xref>]. Recent work from the Netherlands has shown a lack of association between this polymorphism and risk for conotruncal heart defects [<xref ref-type="bibr" rid="B42">42</xref>] as well as no increased risks for a broader phenotypic group of heart defects [<xref ref-type="bibr" rid="B43">43</xref>]. In this study, the 66A&#x0003e;G polymorphism was not associated with increased risks for either spina bifida or conotruncal heart defects. We did observe, however, approximately 3-fold elevated risks for spina bifida associated with three other <italic>MTRR </italic>SNPs (rs162036, rs10380, and rs9332). The significance of these observations will have to be explored in future studies.</p><p>With respect to <italic>MTHFD1 </italic>and <italic>MTHFD2</italic>, two studies have demonstrated an association with one polymorphism (rs 2236225) in <italic>MTHFD1 </italic>and NTD risk. One study showed a 1.5-fold increase in risk of an NTD-affected pregnancy in Irish women who were homozygous AA [<xref ref-type="bibr" rid="B44">44</xref>], a finding that confirmed an earlier increased risk that was identified in Irish women. Another study showed a similar risk for Italian women as well as a 1.9-fold risk for infants with the AA genotype to have spina bifida [<xref ref-type="bibr" rid="B45">45</xref>]. For this particular SNP, we observed a similar magnitude of risk (OR = 1.6) for infants with the homozygous genotype, but the estimate was relatively imprecise. We did observe a modestly elevated spina bifida risk for individuals who were homozygous for another <italic>MTHFD1 </italic>SNP (rs2236224) and modestly lowered risks for three others (hcv11462908, rs702465, and rs7571842). These observations will need to be replicated in future studies.</p><p>Polymorphisms in the <italic>DHFR </italic>gene have not been well-studied for their role in risks of birth defects. Three studies have investigated a 19-bp deletion with mixed results [<xref ref-type="bibr" rid="B46">46</xref>-<xref ref-type="bibr" rid="B48">48</xref>]. That particular polymorphism was not interrogated in the current study.</p><p>Our analyses did not show associations with SNPs in <italic>RFC1</italic>. Previous investigations of this gene have focused on a particular SNP, rs1051266, and have found mixed results [<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B49">49</xref>-<xref ref-type="bibr" rid="B53">53</xref>]. This particular SNP was not analyzed here as a result of too many samples failing to be genotyped for this SNP using the SNPlex platform.</p><p>Recent studies have focused on the importance of <italic>TYMS </italic>in the folate metabolic pathway, including associations between <italic>TYMS </italic>polymorphisms and folate levels [<xref ref-type="bibr" rid="B54">54</xref>-<xref ref-type="bibr" rid="B56">56</xref>]. This folate-dependent enzyme catalyzes the reductive methylation of deoxyuridylate (dUMP) to thymidylate (dTMP), thereby playing a central role in DNA synthesis and repair by serving as the primary intracellular source of dTMP [<xref ref-type="bibr" rid="B54">54</xref>,<xref ref-type="bibr" rid="B57">57</xref>-<xref ref-type="bibr" rid="B59">59</xref>]. We previously [<xref ref-type="bibr" rid="B56">56</xref>] observed a 4-fold increased risk of spina bifida in nonHispanic white infants who had a polymorphism for a 28 bp insertion in the promoter region. This observation, however, was not replicated in a population from the northern UK [<xref ref-type="bibr" rid="B55">55</xref>]. This particular polymorphism was not interrogated in the current study. Three of the five <italic>TYMS </italic>SNPs (rs284179, rs1001761, and rs502396) investigated here showed elevated risks for spina bifida for both heterozygote or homozygote individuals. This finding and the corresponding haplotype finding (Table <xref ref-type="table" rid="T3">3</xref>) will be important to explore in future studies.</p><p>The strengths of this study were: 1) it investigated the potential effects of a large number of folate pathway SNPs, as well as investigated haplotype associations; 2) it had population-based ascertainment of two case phenotypes and controls; and 3) it included cases and controls born before the US food supply was fortified with folic acid, thus we would expect a sizable proportion of cases to have been folate-responsive.</p><p>Conversely, our study was limited in its effect estimation owing to small sample sizes for some comparisons. For example, our study had 80% power to detect risks of 2.5 or more associated with genotypes that were observed in at least 4% of controls. Another potential limitation is the lack of information on maternal folate status. Our working hypothesis is that transient elevation in maternal serum folate from supplementation or dietary intake could prevent birth defects by overcoming metabolic inefficiencies or transport-related issues. Absence of information on low folate status would make it more difficult to find putative genotypes. It is also possible that the protective effect of folic acid relates to correction of a maternal metabolic defect, rather than the fetus. Our study was limited to infant genotype information. Thus, we were unable to investigate the potential effects of maternal genotype. As with any study that seeks to explore associations with a large number of genotypes, findings are subject to chance owing to multiple comparisons. As noted above, we conducted 472 analytic comparisons and thus expected more "statistically significant" findings to arise by chance alone. Further, our findings may have been influenced by uncontrolled confounding by population stratification undetectable in analyses stratified or adjusted by race/ethnicity [<xref ref-type="bibr" rid="B60">60</xref>,<xref ref-type="bibr" rid="B61">61</xref>]. Lastly, the selected SNPs represent only a fraction of the potential variation of the studied genes. Thus, full gene coverage was not achieved even though a large number of SNPs was studied.</p></sec><sec><title>Conclusion</title><p>Despite compelling evidence that folate intake by women in early pregnancy substantially reduces risks of selected birth defects, the underlying mechanisms have not been elucidated. Our study attempted to determine genetic mechanisms responsible for folic acid's preventive effects. Our observations do not implicate a particular folate transport or metabolism gene to be strongly associated with risks for spina bifida or conotruncal defects. Although we explored a sizable number of polymorphic areas in these genes, we clearly did not capture all the genetic variation. Thus, these genes may continue to be candidates for further inquiry. Alternatively, the preventive role of folate may be via other biological mechanisms such as methylation of nonfolate-related genes that participate in the closure of the neural tube or the development of the heart.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>GMS conceived of the study and participated in the statistical analysis. WL conducted the molecular genetic studies. HZ conducted the molecular genetic studies and participated in the statistical analysis. WY conducted the statistical analysis. FBSB conducted the statistical analysis. SLC participated in the statistical analysis. LFB designed and participated in the statistical analysis. EJL conceived of the study and participated in the statistical analysis. RHF conceived of the study and directed the laboratory molecular genetic studies. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/10/49/prepub"/></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Appendix</bold>. Risks of spina bifida and conotruncal heart defects among California infants associated with 118 SNPs in 14 genes involved in folate metabolism or transport relative to nonmalformed population-based controls.</p></caption><media xlink:href="1471-2350-10-49-S1.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>This research was supported by funds from the Centers for Disease Control and Prevention, Center of Excellence Award U50/CCU913241, by NIH/NHLBI R01 HL085859, and by NIH/NINDS R01 NS050249. We thank the California Department of Public Health Maternal Child and Adolescent Health Division for providing data for these analyses. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the California Department of Public Health.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><article-title>Prevention of neural tube defects: results of the Medical Research Council vitamin study. MRC Vitamin Study Research Group</article-title><source>Lancet</source><year>1991</year><volume>338</volume><fpage>131</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">1677062</pub-id><pub-id pub-id-type="doi">10.1016/0140-6736(91)90133-A</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Czeizel</surname><given-names>AE</given-names></name><name><surname>Dud&#x003ac;s</surname><given-names>I</given-names></name></person-group><article-title>Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation</article-title><source>N Engl J Med</source><year>1992</year><volume>327</volume><fpage>1832</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">1307234</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Lammer</surname><given-names>EJ</given-names></name><name><surname>Wasserman</surname><given-names>CR</given-names></name><name><surname>O'Malley</surname><given-names>CD</given-names></name><name><surname>Tolarova</surname><given-names>MM</given-names></name></person-group><article-title>Risks of orofacial clefts in children born to women using multivitamins containing folic acid periconceptionally</article-title><source>Lancet</source><year>1995</year><volume>346</volume><fpage>393</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7623568</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(95)92778-6</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>O'Malley</surname><given-names>CD</given-names></name><name><surname>Wasserman</surname><given-names>CR</given-names></name><name><surname>Tolarova</surname><given-names>MM</given-names></name><name><surname>Lammer</surname><given-names>EJ</given-names></name></person-group><article-title>Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring</article-title><source>Am J Med Genet</source><year>1995</year><volume>59</volume><fpage>536</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">8585581</pub-id><pub-id pub-id-type="doi">10.1002/ajmg.1320590428</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Botto</surname><given-names>LD</given-names></name><name><surname>Mulinare</surname><given-names>J</given-names></name><name><surname>Erickson</surname><given-names>JD</given-names></name></person-group><article-title>Occurrence of congenital heart defects in relation to maternal multivitamin use</article-title><source>Am J Epidemiol</source><year>2000</year><volume>151</volume><fpage>878</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">10791560</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Czeizel</surname><given-names>AE</given-names></name><name><surname>T&#x000fc;th</surname><given-names>M</given-names></name><name><surname>Rockenbauer</surname><given-names>M</given-names></name></person-group><article-title>Population-based case-control study of folic acid supplementation during pregnancy</article-title><source>Teratology</source><year>1996</year><volume>53</volume><fpage>345</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">8910980</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1096-9926(199606)53:6&#x0003c;345::AID-TERA5&#x0003e;3.0.CO;2-Z</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Werler</surname><given-names>MM</given-names></name><name><surname>Hayes</surname><given-names>C</given-names></name><name><surname>Louik</surname><given-names>C</given-names></name><name><surname>Shapiro</surname><given-names>S</given-names></name><name><surname>Mitchell</surname><given-names>AA</given-names></name></person-group><article-title>Multivitamin supplementation and risk of birth defects</article-title><source>Am J Epidemiol</source><year>1999</year><volume>150</volume><fpage>675</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">10512421</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loffredo</surname><given-names>LC</given-names></name><name><surname>Souza</surname><given-names>JM</given-names></name><name><surname>Freitas</surname><given-names>JA</given-names></name><name><surname>Mossey</surname><given-names>PA</given-names></name></person-group><article-title>Oral clefts and vitamin supplementation</article-title><source>Cleft Palate Craniofac J</source><year>2001</year><volume>38</volume><fpage>76</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">11204686</pub-id><pub-id pub-id-type="doi">10.1597/1545-1569(2001)038&#x0003c;0076:OCAVS&#x0003e;2.0.CO;2</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Itikala</surname><given-names>PR</given-names></name><name><surname>Watkins</surname><given-names>ML</given-names></name><name><surname>Mulinare</surname><given-names>J</given-names></name><name><surname>Moore</surname><given-names>CA</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Maternal multivitamin use and orofacial clefts in offspring</article-title><source>Teratology</source><year>2001</year><volume>63</volume><fpage>79</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">11241430</pub-id><pub-id pub-id-type="doi">10.1002/1096-9926(200102)63:2&#x0003c;79::AID-TERA1013&#x0003e;3.0.CO;2-3</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Czeizel</surname><given-names>AE</given-names></name></person-group><article-title>Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation</article-title><source>Am J Med Genet</source><year>1996</year><volume>62</volume><fpage>179</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">8882400</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19960315)62:2&#x0003c;179::AID-AJMG12&#x0003e;3.0.CO;2-L</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Czeizel</surname><given-names>AE</given-names></name><name><surname>Dob&#x000f3;</surname><given-names>M</given-names></name><name><surname>Vargha</surname><given-names>P</given-names></name></person-group><article-title>Hungarian cohort-controlled trial of periconceptional multivitamin supplementation shows a reduction in certain congenital abnormalities</article-title><source>Birth Defects Res A Clin Mol Teratol</source><year>2004</year><volume>70</volume><fpage>853</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">15523663</pub-id><pub-id pub-id-type="doi">10.1002/bdra.20086</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Put</surname><given-names>NM van der</given-names></name><name><surname>Steegers-Theunissen</surname><given-names>RP</given-names></name><name><surname>Frosst</surname><given-names>P</given-names></name><name><surname>Trijbels</surname><given-names>FJ</given-names></name><name><surname>Eskes</surname><given-names>TK</given-names></name><name><surname>Heuvel</surname><given-names>LP van den</given-names></name><name><surname>Mariman</surname><given-names>EC</given-names></name><name><surname>den Heyer</surname><given-names>M</given-names></name><name><surname>Rozen</surname><given-names>R</given-names></name><name><surname>Blom</surname><given-names>HJ</given-names></name></person-group><article-title>Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida</article-title><source>Lancet</source><year>1995</year><volume>346</volume><fpage>1070</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">7564788</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(95)91743-8</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Put</surname><given-names>NM van der</given-names></name><name><surname>Heuvel</surname><given-names>LP van den</given-names></name><name><surname>Steegers-Theunissen</surname><given-names>RP</given-names></name><name><surname>Trijbels</surname><given-names>FJ</given-names></name><name><surname>Eskes</surname><given-names>TK</given-names></name><name><surname>Mariman</surname><given-names>EC</given-names></name><name><surname>den Heyer</surname><given-names>M</given-names></name><name><surname>Blom</surname><given-names>HJ</given-names></name></person-group><article-title>Decreased methylene tetrahydrofolate reductase activity due to the 677C--&#x0003e;T mutation in families with spina bifida offspring</article-title><source>J Mol Med</source><year>1996</year><volume>74</volume><fpage>691</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">8956155</pub-id><pub-id pub-id-type="doi">10.1007/s001090050073</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kirke</surname><given-names>PN</given-names></name><name><surname>Mills</surname><given-names>JL</given-names></name><name><surname>Whitehead</surname><given-names>AS</given-names></name><name><surname>Molloy</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>JM</given-names></name></person-group><article-title>Methylenetetrahydrofolate reductase mutation and neural tube defects</article-title><source>Lancet</source><year>1996</year><volume>348</volume><fpage>1037</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8855891</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(05)64971-9</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Rozen</surname><given-names>R</given-names></name><name><surname>Finnell</surname><given-names>RH</given-names></name><name><surname>Wasserman</surname><given-names>CR</given-names></name><name><surname>Lammer</surname><given-names>EJ</given-names></name></person-group><article-title>Maternal vitamin use, genetic variations of infant methylene tetrahydrofolate reductase and risk for spina bifida</article-title><source>Am J Epidemiol</source><year>1998</year><volume>148</volume><fpage>30</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9663401</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Posey</surname><given-names>DL</given-names></name><name><surname>Khoury</surname><given-names>MJ</given-names></name><name><surname>Mulinare</surname><given-names>J</given-names></name><name><surname>Admas</surname><given-names>MJ</given-names><suffix>Jr</suffix></name><name><surname>Ou</surname><given-names>CY</given-names></name></person-group><article-title>Is mutated MTHFR a risk factor for neural tube defects?</article-title><source>Lancet</source><year>1996</year><volume>347</volume><fpage>686</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8596396</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(96)91236-2</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Botto</surname><given-names>LD</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name></person-group><article-title>5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review</article-title><source>Am J Epidemiol</source><year>2000</year><volume>151</volume><fpage>862</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">10791559</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Junker</surname><given-names>R</given-names></name><name><surname>Kotthoff</surname><given-names>S</given-names></name><name><surname>Vielhaber</surname><given-names>H</given-names></name><name><surname>Halimeh</surname><given-names>S</given-names></name><name><surname>Kosch</surname><given-names>A</given-names></name><name><surname>Koch</surname><given-names>HG</given-names></name><name><surname>Kassenb&#x000f6;hmer</surname><given-names>R</given-names></name><name><surname>Heineking</surname><given-names>B</given-names></name><name><surname>Nowak-G&#x000f6;ttl</surname><given-names>U</given-names></name></person-group><article-title>Infant methylenetetrahydrofolate reductase 677TT genotype is a risk factor for congenital heart disease</article-title><source>Cardiovas Res</source><year>2001</year><volume>51</volume><fpage>251</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/S0008-6363(01)00286-3</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wenstrom</surname><given-names>KD</given-names></name><name><surname>Johanning</surname><given-names>GL</given-names></name><name><surname>Johnston</surname><given-names>KE</given-names></name><name><surname>DuBard</surname><given-names>M</given-names></name></person-group><article-title>Association of the C677T methylenetetrahydrofolate reductase mutation and elevated homocysteine levels with congenital cardiac malformations</article-title><source>Am J Obstet Gynecol</source><year>2001</year><volume>184</volume><fpage>806</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">11303187</pub-id><pub-id pub-id-type="doi">10.1067/mob.2001.113845</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Croen</surname><given-names>LA</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Jensvold</surname><given-names>NJ</given-names></name><name><surname>Harris</surname><given-names>JA</given-names></name></person-group><article-title>Birth defects monitoring in California: a resource for epidemiological research</article-title><source>Paediatr Perinat Epidemiol</source><year>1991</year><volume>5</volume><fpage>423</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">1754501</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-3016.1991.tb00728.x</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulman</surname><given-names>J</given-names></name><name><surname>Hahn</surname><given-names>JA</given-names></name></person-group><article-title>Quality control of birth defects registry data: a case study</article-title><source>Publ Health Rep</source><year>1993</year><volume>108</volume><fpage>91</fpage><lpage>8</lpage></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lovmar</surname><given-names>L</given-names></name><name><surname>Syv&#x000e4;nen</surname><given-names>AC</given-names></name></person-group><article-title>Multiple displacement amplification to create a long-lasting source of DNA for genetic studies</article-title><source>Hum Mutat</source><year>2006</year><volume>27</volume><fpage>603</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">16786504</pub-id><pub-id pub-id-type="doi">10.1002/humu.20341</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holbrook</surname><given-names>JF</given-names></name><name><surname>Stabley</surname><given-names>D</given-names></name><name><surname>Sol-Church</surname><given-names>K</given-names></name></person-group><article-title>Exploring whole genome amplification as a DNA recovery tool for molecular genetic studies</article-title><source>J Biomol Tech</source><year>2005</year><volume>16</volume><fpage>125</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">16030319</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bergen</surname><given-names>AW</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Haque</surname><given-names>KA</given-names></name><name><surname>Welch</surname><given-names>RA</given-names></name><name><surname>Chanock</surname><given-names>SJ</given-names></name></person-group><article-title>Effects of DNA mass on multiple displacement whole genome amplification and genotyping performance</article-title><source>BMC Biotechnol</source><year>2005</year><volume>5</volume><fpage>24</fpage><pub-id pub-id-type="pmid">16168060</pub-id><pub-id pub-id-type="doi">10.1186/1472-6750-5-24</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fredicksen</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>K</given-names></name><name><surname>Ueland</surname><given-names>PM</given-names></name><name><surname>Vollset</surname><given-names>SE</given-names></name><name><surname>Grotmol</surname><given-names>T</given-names></name><name><surname>Schneede</surname><given-names>J</given-names></name></person-group><article-title>Large-scale population-based metabolic phenotyping of thirteen genetic polymorphisms related to one-carbon metabolism</article-title><source>Human Mut</source><year>2007</year><volume>28</volume><fpage>856</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1002/humu.20522</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piedrahita</surname><given-names>JA</given-names></name><name><surname>Oetma</surname><given-names>B</given-names></name><name><surname>Bennett</surname><given-names>GD</given-names></name><name><surname>van Waes</surname><given-names>J</given-names></name><name><surname>Kamen</surname><given-names>BA</given-names></name><name><surname>Richardson</surname><given-names>J</given-names></name><name><surname>Lacey</surname><given-names>SW</given-names></name><name><surname>Anderson</surname><given-names>RG</given-names></name><name><surname>Finnell</surname><given-names>RH</given-names></name></person-group><article-title>Mice lacking the folic-acid binding protein Folbp1 are defective in early embryonic development</article-title><source>Nat Genet</source><year>1999</year><volume>23</volume><fpage>228</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">10508523</pub-id><pub-id pub-id-type="doi">10.1038/13861</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linden</surname><given-names>IJ van der</given-names></name><name><surname>Afman</surname><given-names>LA</given-names></name><name><surname>Heil</surname><given-names>SG</given-names></name><name><surname>Blom</surname><given-names>HJ</given-names></name></person-group><article-title>Genetic variation in genes of folate metabolism and neural-tube defect risk</article-title><source>Proc Nutr Soc</source><year>2006</year><volume>65</volume><fpage>204</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">16672082</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boyles</surname><given-names>AL</given-names></name><name><surname>Billups</surname><given-names>AV</given-names></name><name><surname>Deak</surname><given-names>KL</given-names></name><name><surname>Siegel</surname><given-names>DG</given-names></name><name><surname>Mehltretter</surname><given-names>L</given-names></name><name><surname>Slifer</surname><given-names>SH</given-names></name><name><surname>Bassuk</surname><given-names>AG</given-names></name><name><surname>Kessler</surname><given-names>JA</given-names></name><name><surname>Reed</surname><given-names>MC</given-names></name><name><surname>Nijhout</surname><given-names>HF</given-names></name><name><surname>George</surname><given-names>TM</given-names></name><name><surname>Enterline</surname><given-names>DS</given-names></name><name><surname>Gilbert</surname><given-names>JR</given-names></name><name><surname>Speer</surname><given-names>MC</given-names></name><collab>NTD Collaborative Group</collab></person-group><article-title>Neural tube defects and folate pathway genes: family-based association tests of gene-gene and gene-environment interactions</article-title><source>Environ Health Perspect</source><year>2006</year><volume>114</volume><fpage>1547</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">17035141</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hobbs</surname><given-names>CA</given-names></name><name><surname>James</surname><given-names>SJ</given-names></name><name><surname>Parsian</surname><given-names>A</given-names></name><name><surname>Krakowiak</surname><given-names>PA</given-names></name><name><surname>Jerrigan</surname><given-names>S</given-names></name><name><surname>Greenhaw</surname><given-names>JJ</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Cleves</surname><given-names>MA</given-names></name></person-group><article-title>Congenital heart defects and genetic variants in the methylenetetrahydrofolate reductase gene</article-title><source>J Med Genet</source><year>2006</year><volume>43</volume><fpage>162</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15951337</pub-id><pub-id pub-id-type="doi">10.1136/jmg.2005.032656</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Iovannisci</surname><given-names>DM</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Finnell</surname><given-names>RH</given-names></name><name><surname>Carmichael</surname><given-names>SL</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Lammer</surname><given-names>EJ</given-names></name></person-group><article-title>Risks of human conotruncal heart defects associated with 32 single nucleotide polymorphisms of selected cardiovascular disease-related genes</article-title><source>Am J Med Genet A</source><year>2005</year><volume>138</volume><fpage>21</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16100725</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Storti</surname><given-names>S</given-names></name><name><surname>Vittorini</surname><given-names>S</given-names></name><name><surname>Lascone</surname><given-names>MR</given-names></name><name><surname>Sacchelli</surname><given-names>M</given-names></name><name><surname>Collavoli</surname><given-names>A</given-names></name><name><surname>Ripoli</surname><given-names>A</given-names></name><name><surname>Cocchi</surname><given-names>G</given-names></name><name><surname>Biagini</surname><given-names>A</given-names></name><name><surname>Clerico</surname><given-names>A</given-names></name></person-group><article-title>Association between 5,10-methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and conotruncal heart defects</article-title><source>Clin Chem Lab Med</source><year>2003</year><volume>41</volume><fpage>276</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">12705333</pub-id><pub-id pub-id-type="doi">10.1515/CCLM.2003.043</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Elmore</surname><given-names>CL</given-names></name><name><surname>Lawrance</surname><given-names>AK</given-names></name><name><surname>Matthews</surname><given-names>RG</given-names></name><name><surname>Rozen</surname><given-names>R</given-names></name></person-group><article-title>Methionine synthase reductase deficiency results in adverse reproductive outcomes and congenital heart defects in mice</article-title><source>Mol Genet Metab</source><year>2008</year><volume>94</volume><fpage>336</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">18413293</pub-id><pub-id pub-id-type="doi">10.1016/j.ymgme.2008.03.004</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Wicker</surname><given-names>NJ</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Lammer</surname><given-names>EJ</given-names></name><name><surname>Hendricks</surname><given-names>K</given-names></name><name><surname>Suarez</surname><given-names>L</given-names></name><name><surname>Canfield</surname><given-names>M</given-names></name><name><surname>Finnell</surname><given-names>RH</given-names></name></person-group><article-title>Homocysteine remethylation enzyme polymorphisms and increased risks for neural tube defects</article-title><source>Mol Genet Metab</source><year>2003</year><volume>78</volume><fpage>216</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">12649067</pub-id><pub-id pub-id-type="doi">10.1016/S1096-7192(03)00008-8</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doolin</surname><given-names>MT</given-names></name><name><surname>Barbaux</surname><given-names>S</given-names></name><name><surname>McDonnell</surname><given-names>M</given-names></name><name><surname>Hoess</surname><given-names>K</given-names></name><name><surname>Whitehead</surname><given-names>AS</given-names></name><name><surname>Mitchell</surname><given-names>LE</given-names></name></person-group><article-title>Maternal genetic effects, exerted by genes involved in homocysteine remethylation, influence the risk of spina bifida</article-title><source>Am J Hum Genet</source><year>2002</year><volume>71</volume><fpage>1222</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12375236</pub-id><pub-id pub-id-type="doi">10.1086/344209</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gu&#x000e7;ant-Rodriguez</surname><given-names>RM</given-names></name><name><surname>Rendeli</surname><given-names>C</given-names></name><name><surname>Namour</surname><given-names>B</given-names></name><name><surname>Venuti</surname><given-names>L</given-names></name><name><surname>Romano</surname><given-names>A</given-names></name><name><surname>Anello</surname><given-names>G</given-names></name><name><surname>Bosco</surname><given-names>P</given-names></name><name><surname>Debard</surname><given-names>R</given-names></name><name><surname>G&#x000e7;rard</surname><given-names>P</given-names></name><name><surname>Viola</surname><given-names>M</given-names></name><name><surname>Salvaggio</surname><given-names>E</given-names></name><name><surname>Gu&#x000e7;ant</surname><given-names>JL</given-names></name></person-group><article-title>Transcobalamin and methionine synthase reductase mutated polymorphisms aggravate the risk of neural tube defects in humans</article-title><source>Neurosci Lett</source><year>2003</year><volume>344</volume><fpage>189</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">12812837</pub-id><pub-id pub-id-type="doi">10.1016/S0304-3940(03)00468-3</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Marco</surname><given-names>P</given-names></name><name><surname>Calevo</surname><given-names>MG</given-names></name><name><surname>Moroni</surname><given-names>A</given-names></name><name><surname>Arata</surname><given-names>L</given-names></name><name><surname>Merello</surname><given-names>E</given-names></name><name><surname>Finnell</surname><given-names>RH</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Andreussi</surname><given-names>L</given-names></name><name><surname>Cama</surname><given-names>A</given-names></name><name><surname>Capra</surname><given-names>V</given-names></name></person-group><article-title>Study of MTHFR and MS polymorphisms as risk factors for NTD in the Italian population</article-title><source>J Hum Genet</source><year>2002</year><volume>47</volume><fpage>319</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">12111380</pub-id><pub-id pub-id-type="doi">10.1007/s100380200043</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Leary</surname><given-names>VB</given-names></name><name><surname>Mills</surname><given-names>JL</given-names></name><name><surname>Pangilinan</surname><given-names>F</given-names></name><name><surname>Kirke</surname><given-names>PN</given-names></name><name><surname>Cox</surname><given-names>C</given-names></name><name><surname>Conley</surname><given-names>M</given-names></name><name><surname>Weiler</surname><given-names>A</given-names></name><name><surname>Peng</surname><given-names>K</given-names></name><name><surname>Shane</surname><given-names>B</given-names></name><name><surname>Scott</surname><given-names>JM</given-names></name><name><surname>Parle-McDermott</surname><given-names>A</given-names></name><name><surname>Molly</surname><given-names>AM</given-names></name><name><surname>Brody</surname><given-names>LC</given-names></name><collab>Members of the Birth Defects Research Group</collab></person-group><article-title>Analysis of methionine synthase reductase polymorphisms for neural tube defects risk association</article-title><source>Mol Genet Metab</source><year>2005</year><volume>85</volume><fpage>220</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15979034</pub-id><pub-id pub-id-type="doi">10.1016/j.ymgme.2005.02.003</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>R</given-names></name><name><surname>Zou</surname><given-names>CG</given-names></name></person-group><article-title>Redox regulation and reaction mechanism of human cystathionine-B-synthase: a PLP-dependent hemesensor protein</article-title><source>Arch Biochem Biophys</source><year>2005</year><volume>433</volume><fpage>144</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">15581573</pub-id><pub-id pub-id-type="doi">10.1016/j.abb.2004.08.037</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>A</given-names></name><name><surname>Platt</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Leclerc</surname><given-names>D</given-names></name><name><surname>Christensen</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Gravel</surname><given-names>RA</given-names></name><name><surname>Rozen</surname><given-names>R</given-names></name></person-group><article-title>A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida</article-title><source>Mol Genet Metab</source><year>1999</year><volume>67</volume><fpage>317</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">10444342</pub-id><pub-id pub-id-type="doi">10.1006/mgme.1999.2879</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Candito</surname><given-names>M</given-names></name><name><surname>Rivet</surname><given-names>R</given-names></name><name><surname>Herbeth</surname><given-names>B</given-names></name><name><surname>Boisson</surname><given-names>C</given-names></name><name><surname>Rudigoz</surname><given-names>RC</given-names></name><name><surname>Luton</surname><given-names>D</given-names></name><name><surname>Journel</surname><given-names>H</given-names></name><name><surname>Oury</surname><given-names>JF</given-names></name><name><surname>Rouv</surname><given-names>F</given-names></name><name><surname>Saura</surname><given-names>R</given-names></name><name><surname>Vernhet</surname><given-names>I</given-names></name><name><surname>Gaucherand</surname><given-names>P</given-names></name><name><surname>Muller</surname><given-names>F</given-names></name><name><surname>Guidicelli</surname><given-names>B</given-names></name><name><surname>Heckenroth</surname><given-names>H</given-names></name><name><surname>Poulain</surname><given-names>P</given-names></name><name><surname>Blayau</surname><given-names>M</given-names></name><name><surname>Francannet</surname><given-names>C</given-names></name><name><surname>Roszy</surname><given-names>KL</given-names></name><name><surname>Brusti&#x000e7;</surname><given-names>C</given-names></name><name><surname>Staccini</surname><given-names>P</given-names></name><name><surname>G&#x000e7;rard</surname><given-names>P</given-names></name><name><surname>Fillion-Emery</surname><given-names>N</given-names></name><name><surname>Gu&#x000e7;ant-Rodriguez</surname><given-names>RM</given-names></name><name><surname>Van Obberghen</surname><given-names>E</given-names></name><name><surname>Gu&#x000e7;ant</surname><given-names>JL</given-names></name></person-group><article-title>Nutritional and genetic determinants of vitamin B and homocysteine metabolisms in neural tube defects: a multicenter case-control study</article-title><source>Am J Med Genet Part A</source><year>2008</year><volume>146A</volume><fpage>1128</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.32199</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Relton</surname><given-names>CL</given-names></name><name><surname>Wilding</surname><given-names>CS</given-names></name><name><surname>Laffling</surname><given-names>AJ</given-names></name><name><surname>Jonas</surname><given-names>PA</given-names></name><name><surname>Burgess</surname><given-names>T</given-names></name><name><surname>Binks</surname><given-names>K</given-names></name><name><surname>Tawn</surname><given-names>EJ</given-names></name><name><surname>Burn</surname><given-names>J</given-names></name></person-group><article-title>Low erythrocyte folate status and polymorphic variation in folate-related genes are associated with risk of neural tube defect pregnancy</article-title><source>Mol Genet Metabol</source><year>2004</year><volume>81</volume><fpage>273</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2003.12.010</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Beynum</surname><given-names>IM</given-names></name><name><surname>Kouwenberg</surname><given-names>M</given-names></name><name><surname>Kapusta</surname><given-names>L</given-names></name><name><surname>den Heijer</surname><given-names>M</given-names></name><name><surname>Linden</surname><given-names>IJ van der</given-names></name><name><surname>Daniels</surname><given-names>O</given-names></name><name><surname>Blom</surname><given-names>HJ</given-names></name></person-group><article-title>MTRR 66A&#x0003e;G polymorphism in relation to congenital heart defects</article-title><source>Clin Chem Lab Med</source><year>2006</year><volume>44</volume><fpage>1317</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">17087642</pub-id><pub-id pub-id-type="doi">10.1515/CCLM.2006.254</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verkleij-Hagoort</surname><given-names>AC</given-names></name><name><surname>van Driel</surname><given-names>LM</given-names></name><name><surname>Lindemans</surname><given-names>J</given-names></name><name><surname>Isaacs</surname><given-names>A</given-names></name><name><surname>Steegers</surname><given-names>EA</given-names></name><name><surname>Helbing</surname><given-names>WA</given-names></name><name><surname>Uitterlinden</surname><given-names>AG</given-names></name><name><surname>Steegers-Theunissen</surname><given-names>RP</given-names></name></person-group><article-title>Genetic lifestyle factors related to the periconception vitamin B12 status and congenital heart defects: a Dutch case-control study</article-title><source>Mol Genet Metab</source><year>2008</year><volume>94</volume><fpage>112</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18226574</pub-id><pub-id pub-id-type="doi">10.1016/j.ymgme.2007.12.002</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parle-McDermott</surname><given-names>A</given-names></name><name><surname>Kirke</surname><given-names>PN</given-names></name><name><surname>Mills</surname><given-names>JL</given-names></name><name><surname>Molloy</surname><given-names>AM</given-names></name><name><surname>Cox</surname><given-names>C</given-names></name><name><surname>O'Leary</surname><given-names>VB</given-names></name><name><surname>Pangilinan</surname><given-names>F</given-names></name><name><surname>Conley</surname><given-names>M</given-names></name><name><surname>Cleary</surname><given-names>L</given-names></name><name><surname>Brody</surname><given-names>LC</given-names></name><name><surname>Scott</surname><given-names>JM</given-names></name></person-group><article-title>Confirmation of the R653Q polymorphism of the trifunctional C1-synthase enzyme as a maternal risk for neural tube defects in the Irish population</article-title><source>Eur J Hum Genet</source><year>2006</year><volume>14</volume><fpage>768</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">16552426</pub-id><pub-id pub-id-type="doi">10.1038/sj.ejhg.5201603</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Marco</surname><given-names>P</given-names></name><name><surname>Merello</surname><given-names>E</given-names></name><name><surname>Calevo</surname><given-names>MG</given-names></name><name><surname>Mascelli</surname><given-names>S</given-names></name><name><surname>Raso</surname><given-names>A</given-names></name><name><surname>Cama</surname><given-names>A</given-names></name><name><surname>Capra</surname><given-names>V</given-names></name></person-group><article-title>Evaluation of a methylenetetrahydrofolate-dehydrogenase 1958&#x0003e;A polymorphism for neural tube defect risk</article-title><source>J Hum Genet</source><year>2006</year><volume>51</volume><fpage>98</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">16315005</pub-id><pub-id pub-id-type="doi">10.1007/s10038-005-0329-6</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>WG</given-names></name><name><surname>Stenroos</surname><given-names>ES</given-names></name><name><surname>Spychala</surname><given-names>JR</given-names></name><name><surname>Chatkupt</surname><given-names>S</given-names></name><name><surname>Ming</surname><given-names>SX</given-names></name><name><surname>Buyske</surname><given-names>S</given-names></name></person-group><article-title>New 19 bp deletion polymorphism in Intron-1 of dihydrofolate reductase (DHFR): a risk factor for spina bifida acting in mothers during pregnancy?</article-title><source>Am J Med Genet A</source><year>2004</year><volume>124A</volume><fpage>339</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">14735580</pub-id><pub-id pub-id-type="doi">10.1002/ajmg.a.20505</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parle-McDermott</surname><given-names>A</given-names></name><name><surname>Pangilinan</surname><given-names>F</given-names></name><name><surname>Mills</surname><given-names>JL</given-names></name><name><surname>Kirke</surname><given-names>PN</given-names></name><name><surname>Gibney</surname><given-names>ER</given-names></name><name><surname>Troendle</surname><given-names>J</given-names></name><name><surname>O'Leary</surname><given-names>VB</given-names></name><name><surname>Molloy</surname><given-names>AM</given-names></name><name><surname>Conley</surname><given-names>M</given-names></name><name><surname>Scott</surname><given-names>JM</given-names></name><name><surname>Brody</surname><given-names>LC</given-names></name></person-group><article-title>The 19-bp deletion polymorphism in Intron-1 of dihyrofolate reductase (DHFR) may decrease rather than increase risk for spina bifida in the Irish population</article-title><source>Am J Med Genet A</source><year>2007</year><volume>143A</volume><fpage>1174</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">17486595</pub-id><pub-id pub-id-type="doi">10.1002/ajmg.a.31725</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linden</surname><given-names>IJ van der</given-names></name><name><surname>Nguyen</surname><given-names>U</given-names></name><name><surname>Heil</surname><given-names>SG</given-names></name><name><surname>Franke</surname><given-names>B</given-names></name><name><surname>Vloet</surname><given-names>S</given-names></name><name><surname>Gellekink</surname><given-names>H</given-names></name><name><surname>den Heijer</surname><given-names>M</given-names></name><name><surname>Blom</surname><given-names>HJ</given-names></name></person-group><article-title>Variation and expression of dihydrofolate reductase (DHFR) in relation to spina bifida</article-title><source>Mol Genet Met</source><year>2007</year><volume>91</volume><fpage>98</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2007.01.009</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Lammer</surname><given-names>EJ</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Baker</surname><given-names>MW</given-names></name><name><surname>Neri</surname><given-names>E</given-names></name><name><surname>Finnell</surname><given-names>RH</given-names></name></person-group><article-title>Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida</article-title><source>Am J Med Genet</source><year>2002</year><volume>108</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11857541</pub-id><pub-id pub-id-type="doi">10.1002/ajmg.10195</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Lamer</surname><given-names>EJ</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Finnell</surname><given-names>RH</given-names></name></person-group><article-title>Genetic variation of infant reduced folate carrier (A80G) and risk of orofacial and conotruncal heart defects</article-title><source>Am J Epidemiol</source><year>2003</year><volume>158</volume><fpage>747</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">14561664</pub-id><pub-id pub-id-type="doi">10.1093/aje/kwg189</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Ren</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Hao</surname><given-names>L</given-names></name><name><surname>Finnell</surname><given-names>RH</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name></person-group><article-title>Reduced folate carrier gene is a risk factor for neural tube defects in a Chinese population</article-title><source>Birth Defects Res A Clin Mol Teratol</source><year>2005</year><volume>73</volume><fpage>430</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">15799025</pub-id><pub-id pub-id-type="doi">10.1002/bdra.20130</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>A</given-names></name><name><surname>Finnell</surname><given-names>RH</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name></person-group><article-title>Genetic variation of infant reduced folate carrier (A80G) and risk of orofacial defects and congenital heart defects in China</article-title><source>Ann Epidemiol</source><year>2006</year><volume>16</volume><fpage>352</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16019224</pub-id><pub-id pub-id-type="doi">10.1016/j.annepidem.2005.02.014</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Marco</surname><given-names>P</given-names></name><name><surname>Calevo</surname><given-names>MG</given-names></name><name><surname>Moroni</surname><given-names>A</given-names></name><name><surname>Merello</surname><given-names>E</given-names></name><name><surname>Raso</surname><given-names>A</given-names></name><name><surname>Finnell</surname><given-names>RH</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Andreussi</surname><given-names>L</given-names></name><name><surname>Cama</surname><given-names>A</given-names></name><name><surname>Capra</surname><given-names>V</given-names></name></person-group><article-title>Reduced folate carrier polymorphism (80A--&#x0003e;G) and neural tube defects</article-title><source>Eur J Hum Genet</source><year>2003</year><volume>11</volume><fpage>245</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">12673279</pub-id><pub-id pub-id-type="doi">10.1038/sj.ejhg.5200946</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trinh</surname><given-names>BN</given-names></name><name><surname>Ong</surname><given-names>CN</given-names></name><name><surname>Coetzee</surname><given-names>GA</given-names></name><name><surname>Yu</surname><given-names>MC</given-names></name><name><surname>Laird</surname><given-names>PW</given-names></name></person-group><article-title>Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels</article-title><source>Hum Genet</source><year>2002</year><volume>111</volume><fpage>299</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">12215845</pub-id><pub-id pub-id-type="doi">10.1007/s00439-002-0779-2</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilding</surname><given-names>CS</given-names></name><name><surname>Relton</surname><given-names>CL</given-names></name><name><surname>Sutton</surname><given-names>MJ</given-names></name><name><surname>Jonas</surname><given-names>PA</given-names></name><name><surname>Lynch</surname><given-names>SA</given-names></name><name><surname>Tawn</surname><given-names>EJ</given-names></name><name><surname>Burn</surname><given-names>J</given-names></name></person-group><article-title>Thymidylate synthase repeat polymorphisms and risk of neural tube defects in a population from the Northern United Kingdom</article-title><source>Birth Def Res A Clin Mol Teratol</source><year>2004</year><volume>70</volume><fpage>483</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1002/bdra.20038</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Volcik</surname><given-names>KA</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Lammer</surname><given-names>EJ</given-names></name><name><surname>Laurent</surname><given-names>C</given-names></name><name><surname>Finnell</surname><given-names>RH</given-names></name></person-group><article-title>Associations between polymorphisms within the thymidylate synthase gene and spina bifida</article-title><source>Birth Defects Res A Clin Mol Teratol</source><year>2003</year><volume>67</volume><fpage>924</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">14745930</pub-id><pub-id pub-id-type="doi">10.1002/bdra.10029</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Schmitz</surname><given-names>JC</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Tai</surname><given-names>N</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Farrell</surname><given-names>M</given-names></name><name><surname>Bailly</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Chu</surname><given-names>E</given-names></name></person-group><article-title>Thymidylate synthase as a translational regulator of cellular gene expression</article-title><source>Biochim Biophys Acta</source><year>2002</year><volume>1587</volume><fpage>174</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">12084459</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawate</surname><given-names>H</given-names></name><name><surname>Landis</surname><given-names>DM</given-names></name><name><surname>Loeb</surname><given-names>LA</given-names></name></person-group><article-title>Distribution of mutations in human thymidylate synthase yielding resistance to 5-fluorodeoxyuridine</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>36304</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">12147691</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M204956200</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ulrich</surname><given-names>CM</given-names></name><name><surname>Bigler</surname><given-names>J</given-names></name><name><surname>Bostick</surname><given-names>R</given-names></name><name><surname>Fosdick</surname><given-names>L</given-names></name><name><surname>Potter</surname><given-names>JD</given-names></name></person-group><article-title>Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>3361</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">12067974</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>DC</given-names></name><name><surname>Witte</surname><given-names>JS</given-names></name></person-group><article-title>Point: population stratification: a problem for case-control studies of candidate-gene associations?</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2002</year><volume>11</volume><fpage>505</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">12050090</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wacholder</surname><given-names>S</given-names></name><name><surname>Rothman</surname><given-names>N</given-names></name><name><surname>Caporaso</surname><given-names>N</given-names></name></person-group><article-title>Counterpoint: bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2002</year><volume>11</volume><fpage>513</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">12050091</pub-id></citation></ref></ref-list></back></article> 